

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

0026A2/h

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

CONTENT	PAGE(S)
Directors' Report	1 – 15
Statement by Directors	16
Statutory declaration	16
Independent auditors' report	17 – 20
Financial statements	
Statement of financial position	21 – 22
Statement of income	23
Statement of comprehensive income	24
Statement of changes in equity	25
Statement of cash flows	26 – 27
Notes to the financial statements	28 – 115

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT

The Directors have pleasure in submitting their report together with the audited financial statements of the Company for the financial year ended 31 December 2021.

PRINCIPAL ACTIVITY

The Company is engaged principally in the underwriting of life insurance business including investment-linked business. There have been no significant changes in the nature of these activities during the financial year.

FINANCIAL RESULTS

	RM'000
Profit for the financial year	<u>33,199</u>

DIVIDENDS

No dividend has been declared or paid by the Company since the end of the previous financial year.

The Directors do not recommend the payment of any dividend for the current financial year.

RESERVES AND PROVISIONS

All material transfers to or from reserves and provisions during the financial year are disclosed in the financial statements.

SHARE CAPITAL

On 5 May 2021, the Company increased its share capital by RM60,000,000 to RM185,000,000. The summary of capital injection exercise is disclosed in Note 12 to the financial statements.

PROVISION FOR INSURANCE LIABILITIES

Before the financial statements of the Company were prepared, the Directors took reasonable steps to ascertain that there was adequate provision for its insurance liabilities in accordance with the valuation methods specified in Part D of the Risk-Based Capital Framework ("RBC Framework") for licensed insurers issued by Bank Negara Malaysia ("BNM").

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

BAD AND DOUBTFUL DEBTS

Before the financial statements of the Company were prepared, the Directors took reasonable steps to ascertain that action had been taken in relation to the writing off of bad debts and the making of allowance for doubtful debts, and satisfied themselves that all known bad debts had been written off and adequate allowance had been made for doubtful debts.

At the date of this report, the Directors are not aware of any circumstances that would render the amount written off for bad debts or the amount of the allowance for doubtful debts in the financial statements of the Company inadequate to any substantial extent.

CURRENT ASSETS

Before the financial statements of the Company were prepared, the Directors took reasonable steps to ensure that any current assets, other than debts, which were unlikely to be realised in the ordinary course of business, their values as shown in the accounting records of the Company have been written down to an amount which they might be expected to realise.

At the date of this report, the Directors are not aware of any circumstances which would render the values attributed to current assets in the financial statements of the Company misleading.

VALUATION METHODS

At the date of this report, the Directors are not aware of any circumstances which have arisen which render adherence to the existing methods of valuation of assets or liabilities of the Company misleading or inappropriate.

CONTINGENT AND OTHER LIABILITIES

At the date of this report, there does not exist:

- (a) any charge on the assets of the Company that has arisen since the end of the financial year which secures the liabilities of any other person; or
- (b) any contingent liability in respect of the Company that has arisen since the end of the financial year.

No contingent or other liability of the Company has become enforceable or is likely to become enforceable within the year of twelve month after the end of the financial year which, in the opinion of the Directors, will or may substantially affect the ability of the Company to meet its obligations as and when they fall due.

For the purpose of this paragraph, contingent or other liabilities do not include liabilities arising from contracts of insurance underwritten in the ordinary course of business of the Company.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CHANGE OF CIRCUMSTANCES

At the date of this report, the Directors are not aware of any circumstances not otherwise dealt with in this report or the financial statements of the Company which would render any amount stated in the financial statements misleading.

ITEMS OF AN UNUSUAL NATURE

The results of the operations of the Company during the financial year were not, in the opinion of the Directors, substantially affected by any item, transaction or event of a material and unusual nature other than those disclosed in the financial statements.

There has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the Directors, to affect substantially the results of the operations of the Company for the financial year in which this report is made.

DIRECTORS OF THE COMPANY

The directors of the Company who served during the period since the date of the last report are as follows:

Dato' Haji Kamil Khalid Ariff (Non-Independent Non-Executive Director/Chairman)

Dato' Danapalan A/L T.P. Vingrasalam (Independent Non-Executive Director)

Oh Teik Tatt (Independent Non-Executive Director)

Ramesh Pillai (Independent Non-Executive Director)

Jonathan Graybill (Executive Director)

Kameel bin Abdul Halim (Non-Independent Non-Executive Director) (Resigned on 31 January 2022)

Yu Chwee Kum, Rosalind (Independent Non-Executive Director) (Appointed on 30 July 2021)

CORPORATE GOVERNANCE

The Company, with the leadership of the Board of Directors ("the Board"), has adopted the necessary measures to ensure that the corporate and management practices are consistent with the regulatory requirements and best practice standards ordained under BNM/RH/PD/029-9: Corporate Governance issued by BNM. The Company's policy is to achieve best practices in their business standards for all activities throughout the Company and good corporate governance, which the Board fully recognises to be one of its principal responsibilities to protect and enhance shareholder value and financial performance of the Company.

(a) **Key issues and aspects**

Key elements of the industry's corporate governance captured by the Frameworks are:

- i. An effective and balanced Board appointed through a predetermined appointment procedure;
- ii. Executive remuneration set by the Board Remuneration Committee that attracts and retains the people needed to run the Company;
- iii. A sound system of internal controls that safeguards the Company's assets and investments, and identifies and manages business risks; and
- iv. The process in respect to disclosure of conflict of interest situation where arising.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

(a) Key issues and aspects (continued)

The Company's commitment to the corporate governance standards entails the following:

- i. The Board currently comprises seven directors represented by four independent non-executive, two non-independent non-executive and one executive director of calibre, with the necessary skills and diverse corporate experience to ensure that strategies proposed by the management are fully discussed and examined as well as to take into account the long term interests of various stakeholders.
- ii. Executive remuneration is set by the Board Remuneration Committee. The Company's executive remuneration policy is to reward employees competitively, taking into account individual performance, company performance, market comparisons and the competitiveness in the local insurance industry. Remuneration packages are reviewed annually and comprise a mix of basic salary and performance-linked elements.
- iii. The Board is responsible for the Company's system of internal controls and risk management, and reviewing the effectiveness of these systems which are designed to proactively manage, rather than eliminate, the risk of failure to achieve sustainable business objectives. In achieving this, the following are put in place:
 - the Board Risk Management Committee which oversees and provides overall direction on risk management efforts;
 - a system of financial and business controls which provides regular reports by the Chief Executive Officer ("CEO") to the Board;
 - regular assessments of internal controls by the Company's internal audit department; and
 - review of the effectiveness of the internal control processes by the Board Audit Committee, on behalf of the Board.

(b) Board responsibilities

The Board is ultimately responsible for the Company's strategic direction and overseeing the performance of the Company. Its focus is on the following:

- i. Strategic plan
- ii. Organisation development
- iii. Shareholder value
- iv. Oversight and control
- iv. Corporate governance

The detailed responsibilities of the Board are set out in the Board Charter which is available at the website, www.gibraltarbsn.com.

(c) Supply of information

The Board is mindful that its strategic focus on matters relating to their business and its exposures should be based on informed decisions. Hence, all the Directors are provided with the meeting agenda and Board reports well ahead of Board meetings. This is to enable the Directors to obtain further explanations, where necessary, in order to be briefed properly before the meeting. As and when necessary, the Board, in furtherance of their duties may seek independent professional advice at the Company's expense. All the Directors have access to the advice and services of the Company Secretary.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

(d) Profile of the Directors

1. Dato' Haji Kamil Khalid Ariff
Non-Independent Non-Executive Director/Chairman

Dato' Haji Kamil Khalid Ariff was appointed as an Independent Non-Executive Director of Uni Asia Life Insurance Bhd (now known as Gibraltar BSN Life Berhad) on 24 October 2011. After the acquisition of the company by Prudential Insurance Company of America ("Prudential") and Bank Simpanan Nasional ("BSN") on 2 January 2014, Dato' Haji Kamil Khalid remained on the board of the new company Gibraltar BSN Life Bhd. He was subsequently appointed as Chairman of the Board on 20 January 2017. Dato' Haji Kamil Khalid Ariff was redesignated as a Non-Independent Non-Executive Director/Chairman on 19 January 2020. He is currently a member of Board Risk Management, Board Audit, Board Nomination and Board Remuneration Committees.

Dato' Haji Kamil Khalid is currently the Chairman of Liberty Insurance Berhad, Putrajaya Holdings Sdn Bhd and Chairman/Independent Non-Executive Director of Public Islamic Bank Berhad. He also is a director of several private companies. He was formerly an Independent Non-Executive Director of Bank Muamalat Malaysia Bhd.

Dato' Haji Kamil Khalid graduated with MBA in International Business from Michigan, United States of America ("USA") in 1979. Prior to this, he obtained BSc in Management from Syracuse University, New York and the Diploma in Public Administration from ITM. His last position was as Managing Director/Chief Executive Officer of Mahkota Technologies Sdn Bhd (formerly known as General Electric Company of the UK) - dealing mainly in the electrical engineering/supply industry. Upon his retirement he was appointed as Chairman/Director of several other private companies.

Over his illustrious career spanning over 43 years, Dato' Haji Kamil Khalid served in numerous Management and Board positions in several large corporate entities which among others include, The New Straits Times, Kumpulan Perangsang Selangor Bhd, Kumpulan Guthrie Bhd and Idris Hydraulic Bhd. During this time, he was exposed to various multi-faceted industries that is Advertising & Publishing, Trading, Manufacturing and Engineering. He was also a founder Director of the Kuala Lumpur Tin Market, which he, as part of a Government Steering Committee, helped set up in the mid-1980s.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

(d) Profile of the Directors (continued)

2. **Dato' Danapalan A/L T.P. Vinggrasalam**
Independent Non-Executive Director

Dato' Danapalan A/L T.P. Vinggrasalam was appointed as an Independent Non-Executive Director to the Board of Gibraltar BSN Life Berhad on 2 January 2014. He is the Chairman of the Board Risk Management and Board Remuneration Committees and a member of the Board Audit and Board Nomination Committees.

He started his career with the Malaysian Administrative and Diplomatic Services in 1966. He served over 30 years in government service holding positions including Secretary of the Royal Commission on the Teaching Services, Deputy Secretary-General of the Ministry of Social and Community Development and Deputy Director of INTAN. In 1991, he was appointed as the Secretary General of Ministry of Science, Technology and the Environment until his retirement in March 1998. From June 1998 to 2004, he served as Senior Vice President of the Multimedia Development Commission. From 2004 to 2006, Dato' Danapalan was the Chairman and CEO of Malaysian Communication and Multimedia Commission ("MCMC"). He then moved into corporate sector. He was the Senior Independent Director of Telekom Malaysia Berhad. He also held directorships in wholly owned subsidiaries of Telekom Malaysia. He has also served on the boards of BSN, Affin Fund, MUST University, Sirim QAS International Sdn Bhd (a subsidiary of SIRIM Berhad) and Instapay Technologies Sdn Bhd.

Dato' Danapalan is currently a member of the Board of Trustees of Maybank Foundation and Tun Sambanthan Scholarship Fund. He is also member of the Affin Hwang Asset Management Committee.

Dato' Danapalan holds a Bachelor of Arts (Honours) from University of Malaya and a Master of Public Administration from Pennsylvania State University, USA.

3. **Oh Teik Tatt**
Independent Non-Executive Director

Mr Oh Teik Tatt was appointed as an Independent Non-Executive Director on 24 January 2017. He is the Chairman of Board Audit and Board Nomination and a member of Board Risk Management and Board Remuneration Committees.

He was a graduate in Agricultural Science from University of Malaya, and was the Managing Director of Tractors Malaysia Holdings Berhad for 11 years until his retirement in 2004. He was the Chairman of Landmarks Bhd, and is on the Board of a number of companies.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

(d) Profile of the Directors (continued)

4. Ramesh Pillai
Independent Non-Executive Director

Mr Ramesh Pillai was appointed to the Board of Gibraltar BSN Life Berhad on 1 July 2016 as an Independent Non-Executive Director. He is a member of the Board Risk Management, Board Audit, Board Nomination and Board Remuneration Committees.

Mr Ramesh started his career with Price Waterhouse's Financial Institutions specialism in London gaining experience in Audit, Consultancy and Corporate Finance assignments. He possesses more than 35 years of risk management experience, both in the public and private sector and has held various positions, including that of Chairman, Group Managing Director, CEO, Finance Director and Group Chief Risk Officer (in commercial organisations as well as in Conventional and Islamic Financial Institutions). He was also with Pengurusan Danaharta Nasional as its Chief Risk Officer as well as Bank Negara Malaysia as the Head of its Deposit Insurance Taskforce.

Mr Ramesh is currently the Chairman of the Board of Governors of the International Institute of Enterprise Risk Practitioners (IERP® - providing professional certification in Enterprise Risk Management) as well as the Group Managing Director of Friday Concepts (International), an International Boutique Risk Management, Governance and Compliance consultancy and also TriasGRC, a tech startup developing GRC solutions. He is also an Independent Non-Executive Director of AmInvestment Bank Berhad and AmGeneral Insurance Berhad.

Mr Ramesh holds a Bachelor of Science (Honours) in Economics with Accountancy from Loughborough University, United Kingdom, where he specialised in Economics, Accounting and Banking in general, and Islamic Banking in particular. He is a fellow of the Institute of Chartered Accountants in England and Wales (1991) as well as the Malaysian Institute of Accountants, a Certified Enterprise Risk Manager, a Certified Digital Risk Professional, a Certified Risk Professional, a Qualified Risk Director, a certified Islamic Enterprise Risk Manager and a Qualified Risk Auditor.

5. Jonathan Graybill
Executive Director

Mr Jonathan Graybill, Senior Vice President (International Business) of Prudential Financial, Inc. ("PFI") was appointed as an Executive Director of Gibraltar BSN Life Berhad on 18 September 2017. He is a member of the Board Nomination Committee.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

(d) Profile of the Directors (continued)

5. Jonathan Graybill (continued)
Executive Director (continued)

Mr Graybill has a long and successful track record at PFI with more than 30 years of service. He started as an accounting specialist in the Retirement business and subsequently joined the U.S. Individual Life Insurance Operations & Systems where he quickly took on greater responsibilities. He moved to the international division in 2013 as the Head of Operations & Systems and leveraged his experience in the USA to raise the standards across Prudential. The Gibraltar BSN joint venture in Malaysia was formed in 2014, and he led Prudential's efforts to build systems, processes and policies for the partnership to ensure the organisation met its customer commitments. He then moved to Singapore in 2016 as Regional President for the Asia region outside of Japan and has been focused on elevating the quality of talent and reinforcing Prudential's high ethical standards while advancing the growth of the business. Under his leadership, Prudential established the PFI Mega Life joint venture in Indonesia, one of the most complex markets in which Prudential does business. Mr Graybill was promoted to Senior Vice President, International Business in November 2018, in recognition of his strong leadership in highly complex and dynamic business environments.

Mr Graybill holds a Bachelor of Science in Finance from Pennsylvania State University and a Master of Business Administration from Temple University.

6. Kameel bin Abdul Halim
Non-Independent Non-Executive Director

Encik Kameel bin Abdul Halim was appointed as a Non-Independent Non-Executive Director of Gibraltar BSN Life Berhad on 29 March 2018 and resigned on 31 January 2022. During his tenure as a Director, he was a member of the Board Remuneration Committee and the Chief Operating Officer of BSN where he oversaw BSN's banking and credit operations, treasury and investment, digital banking as well as information technology.

Encik Kameel has over 23 years of banking experience comprising both commercial banking, central banking and development finance. He first began his career at HSBC (M) Berhad with exposures in branch operations, trade finance and credit lending. He then left to join the Central Bank of Malaysia where for 12 years, served in several key departments including supervision, surveillance and policy development.

Encik Kameel holds a Master's Degree in Risk Management from University of Nottingham.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

(d) Profile of the Directors (continued)

7. Yu Chwee Kum, Rosalind
Independent Non-Executive Director

Ms Rosalind was appointed to the Board of Gibraltar BSN Life Berhad on 30 July 2021 as an Independent Non-Executive Director.

Ms Rosalind graduated with a BSc (Hons) from Monash University (Australia). She also holds a Graduate Diploma (Marketing) from the Chartered Institute of Marketing (UK) and an MBA from University of South Australia.

She has over 30 years of experience in the Insurance industry, both locally and abroad. Over the span of her career, she has managed both Individual Life and Group businesses as well as heading Customer Service & Branch Operations nationwide.

She is currently the Director of Health and Benefits at Willis Towers Watson, where she is overall responsible for the strategic direction, business operations and talent management to drive business growth.

(e) The Board meetings and attendance for the financial year ended 31 December 2021 are as follows:

<u>Name of Directors</u>	<u>Number of Board meetings (Attended/Held)</u>
Dato' Haji Kamil Khalid Ariff (Chairman)	8/8
Dato' Danapalan A/L T.P. Vinggrasalam	8/8
Oh Teik Tatt	8/8
Ramesh Pillai	8/8
Jonathan Graybill	8/8
Kameel bin Abdul Halim (Resigned on 31 January 2022)	8/8
Yu Chwee Kum, Rosalind (Appointed on 30 July 2021)	4/4

(f) Appointment/re-appointment of Directors

The appointment/re-appointment of the Directors is based on the Company's Articles of Association and were approved by BNM. All the Directors who are appointed by the Board are subject to re-election every succeeding year; thereafter one-third of the Directors (being those who have been longest in office) shall be retired or re-elected.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

(g) Directors' training

Apart from the Financial Institutions Directors' Education ("FIDE") Programme accredited by International Centre for Leadership in Finance ("ICLIF"), the Directors are encouraged to attend continuous education programs and seminars to keep abreast with developments in the industry. The Company also keeps a record of the Directors' training programs and attendance to the said programme.

During the year, the Directors participated in the following event:

- BNM-FIDE FORUM Dialogue with Senior Leaders: "Risk-Based Capital Framework for Insurers and Takaful Operators".

(h) Directors' responsibility statement with respect to the financial statements.

The Directors are required by the Companies Act 2016 to prepare financial statements for each financial year which have been made out in accordance with the Malaysian Financial Reporting Standards ("MFRS"), International Financial Reporting Standards ("IFRS") and comply with the requirements of the Companies Act 2016 in Malaysia and give a true and fair view of the state of affairs of the Company at the end of the financial year and of the results and cash flows of the Company for the financial year.

In preparing the financial statements, the Directors have:

- adopted suitable accounting policies and applied them consistently;
- made judgements and estimates that are reasonable and prudent;
- ensured that all applicable accounting standards have been followed; and
- prepared financial statements on the going concern basis as the Directors have a reasonable expectation, having made enquiries that the Company has adequate resources to continue in operational existence for the foreseeable future.

The Directors have the responsibility for ensuring that the Company keeps accounting records which disclose, with reasonable accuracy, the financial position of the Company and to ensure that the financial statements comply with the requirements of the Companies Act 2016 in Malaysia.

The Directors have overall responsibility to take steps to safeguard the assets of the Company and to prevent and detect fraud and irregularities.

(i) Financial reporting

In presenting the annual financial statements, the Directors aim to present a balanced and understandable assessment of the Company's position and prospects.

(j) Board Committees

The Board has assigned specific responsibilities to four (4) Board committees (Board Audit, Board Remuneration, Board Nomination and Board Risk Management Committees) operating on the terms of reference approved by the Board, to assist the Board in the execution of its responsibilities. Board committees have the authority to examine particular issues and report back to the Board with their recommendations. The ultimate responsibility for the final decision on all matters, however, lies with the Board.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

(k) Board Audit Committee

The Board Audit Committee meetings and attendance for the financial year ended 31 December 2021 are as follows:

<u>Name of Directors</u>	<u>Number of Audit meetings (Attended/Held)</u>
Oh Teik Tatt (Chairman)	6/6
Dato' Haji Kamil Khalid Ariff	6/6
Dato' Danapalan A/L T.P. Vinggrasalam	6/6
Ramesh Pillai	6/6

The Board Audit Committee reviews the Company's accounting policies, systems of internal controls and risk management, reports from the Company's internal and external auditors and determines that appropriate actions are being taken by the management. Its conclusions are reported to the Board, which takes responsibility for the Company's system of internal controls.

The Audit Committee also considers the Company's published financial statements for statutory compliance and best practice standards, and recommends to the Board appropriate disclosure in these reports. It also reviews the performance of the Company's external auditors annually to ensure an objective, professional and cost-effective relationship. It recommends to the Board the external auditors fees for their audit services.

The detailed terms of reference of the Board Audit Committee are set out in the Board Charter which is available at the website, www.gibraltarbsn.com.

(l) Board Remuneration Committee

The Board Remuneration Committee meetings and attendance for the financial year ended 31 December 2021 are as follows:

<u>Name of Directors</u>	<u>Number of Remuneration meetings (Attended/Held)</u>
Dato' Danapalan A/L T.P. Vinggrasalam (Chairman)	3/3
Dato' Haji Kamil Khalid Ariff	3/3
Oh Teik Tatt	3/3
Ramesh Pillai	3/3
Kameel bin Abdul Halim (Resigned on 31 January 2022)	3/3

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

(l) Board Remuneration Committee (continued)

The Board Remuneration Committee recommends the remuneration policy for the Directors, the CEO and senior management reporting to the Board. Specifically, the Remuneration Committee agrees their service/employment contracts, salaries, other benefits, including bonuses and participation in the Company's long-term incentive plans, and other terms and conditions of service/employment.

It also agrees terms for their cessation of service/employment, approves changes in the Company's long term incentive plans, recommends to the Board those plans which require shareholders' approval and oversees their operations.

The detailed terms of reference of the Board Remuneration Committee are set out in the Board Charter which is available at the website, www.gibraltarsn.com.

Remuneration of the Directors and the CEO

The aggregate remuneration of the Directors and the CEO have been disclosed in Note 25 to the financial statements, meeting the minimum requirement of BNM/RH/STD 032-5.

(m) Board Nomination Committee

The Board Nomination Committee meetings and attendance for the financial year ended 31 December 2021 are as follows:

<u>Name of Directors</u>	<u>Number of Nomination meetings (Attended/Held)</u>
Oh Teik Tatt (Chairman)	5/5
Dato' Haji Kamil Khalid Ariff	5/5
Jonathan Graybill	5/5
Dato' Danapalan A/L T.P. Vinggrasalam	5/5
Ramesh Pillai	5/5

The Board Nomination Committee recommends to the Board the appointments of all Directors and senior management, and regularly reviews profile of the skills and attributes required from the Directors as a whole to ensure an appropriate balance of expertise and ability. This profile is used to assess the suitability of candidates put forward by the Directors and shareholders.

The detailed terms of reference of the Board Nomination Committee are set out in the Board Charter which is available at the website, www.gibraltarsn.com.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

(n) Board Risk Management Committee

The Board Risk Management Committee meetings and attendance for the financial year ended 31 December 2021 are as follows:

<u>Name of Directors</u>	<u>Number of Risk meetings (Attended/Held)</u>
Dato' Danapalan A/L T.P. Vinggrasalam (Chairman)	4/4
Dato' Haji Kamil Khalid Ariff	4/4
Ramesh Pillai	4/4
Oh Teik Tatt	4/4

The duties and responsibilities of the Board Risk Management Committee are guided by its approved Terms of Reference by the Board of Directors. The key roles of the committee are as follows:

- (a) To review and approve the Annual Plan of Risk Management and Compliance Department;
- (b) To review and recommend frameworks, policies, risk appetite of Risk Management and Compliance Department for the Board's approval;
- (c) To review and ensure that adequate infrastructure, resources and systems are in place for Risk Management and Compliance Department to effectively carry out their respective responsibilities;
- (d) To receive and review periodic reports from Risk Management and Compliance Department on risk exposure, risk profile, fraud related matters, regulatory developments and compliance events; and
- (e) To review Risk Management and Compliance reports as well as provide recommendations and constructive challenge to Senior Management.

The detailed terms of reference of the Board Risk Management Committee are set out in the Board Charter which is available at the website, www.gibraltarbsn.com.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

CORPORATE GOVERNANCE (CONTINUED)

DIRECTORS' INTERESTS

According to the register of Directors' shareholdings, the Directors in office at the end of the financial year did not hold any interest in shares and options over shares in or debentures of the Company or shares and debentures of its related corporations during the financial year.

DIRECTORS' BENEFITS

During and at the end of the financial year, no arrangements subsisted to which the Company is a party with the object or objects of enabling Directors of the Company to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate.

Since the end of the previous financial year, no Director of the Company has received or become entitled to receive any benefit (other than Directors' remuneration as shown in the financial statements) by reason of a contract made by the Company or a related corporation with the Director or with a firm of which the Director is a member, or with a company in which the Director has a substantial financial interest.

INDEMNITY TO DIRECTORS AND OFFICERS

During the financial year, the total amount of indemnity coverage and insurance premium paid for the Directors and certain officers of the Company were RM50,000,000 and RM117,345 respectively.

SIGNIFICANT EVENT DURING THE FINANCIAL YEAR

Details of the significant event during the financial year is as disclosed in Note 35 to the financial statements.

ULTIMATE HOLDING COMPANY

The Directors regard Gibraltar BSN Holdings Sdn. Bhd. ("GH"), as the immediate holding company; PFI, as the ultimate holding company and The Prudential Insurance Company of America ("PICA"), as the penultimate holding company. PFI and PICA are incorporated in the USA.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

DIRECTORS' REPORT (CONTINUED)

AUDITORS

The auditors, PricewaterhouseCoopers PLT (LLP0014401-LCA & AF 1146), have expressed their willingness to accept re-appointment as auditors.

Details of auditors' remuneration are set out in Note 25 to the financial statements.

There is no indemnity given to or insurance affected for any auditor of the Company.

Signed on behalf of the Board of Directors in accordance with resolution of the Directors dated 25 February 2022.



DATO' HAJI KAMIL KHALID ARIFF
CHAIRMAN



OH TEIK TATT
DIRECTOR

Kuala Lumpur, Wilayah Persekutuan

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**STATEMENT BY DIRECTORS
PURSUANT TO SECTION 251 (2) OF THE COMPANIES ACT 2016**

We, Dato' Haji Kamil Khalid Ariff and Oh Teik Tatt, two of the Directors of Gibraltar BSN Life Berhad, do hereby state that, in the opinion of the Directors, the financial statements set out on pages 21 to 115 are drawn up so as to give a true and fair view of the financial position of the Company as at 31 December 2021 and of its financial performance and the cash flows of the Company for the financial year ended 31 December 2021 in accordance with the Malaysian Financial Reporting Standards ("MFRS"), International Financial Reporting Standards ("IFRS") and the requirements of the Companies Act 2016 in Malaysia.

Signed on behalf of the Board of Directors in accordance with a resolution of the Directors dated 25 February 2022.

DATO' HAJI KAMIL KHALID ARIFF
CHAIRMAN

OH TEIK TATT
DIRECTOR


**STATUTORY DECLARATION
PURSUANT TO SECTION 251 (1) OF THE COMPANIES ACT 2016**

I, Lee Kok Wah, being the officer primarily responsible for the financial management of Gibraltar BSN Life Berhad, do solemnly and sincerely declare that, the financial statements set out on pages 21 to 115 are, in my opinion to the best of my knowledge and belief, correct and I make this solemn declaration conscientiously believing the same to be true, and by virtue of the provisions of the Statutory Declarations Act 1960.

LEE KOK WAH

Subscribed and solemnly declared by the abovenamed Lee Kok Wah at Kuala Lumpur, Wilayah Persekutuan in Malaysia on 25 February 2022.

Before me,



the Spaces
Block B01-B-15
Level 15, Menara 2
KL Eco City
3 Jalan Bangsar
59200 Kuala Lumpur



**INDEPENDENT AUDITORS' REPORT
TO THE MEMBER OF GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)
Registration No. 199301022976 (277714-A)**

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

Our opinion

In our opinion, the financial statements of Gibraltar BSN Life Berhad (“the Company”) give a true and fair view of the financial position of the Company as at 31 December 2021, and of its financial performance and its cash flows for the financial year then ended in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

What we have audited

We have audited the financial statements of the Company, which comprise the statement of financial position as at 31 December 2021, and the statement of income, statement of comprehensive income, statement of changes in equity and statement of cash flows for the financial year then ended, and notes to the financial statements, including a summary of significant accounting policies, as set out on pages 21 to 115.

Basis for opinion

We conducted our audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing. Our responsibilities under those standards are further described in the “Auditors’ responsibilities for the audit of the financial statements” section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence and other ethical responsibilities

We are independent of the Company in accordance with the By-Laws (on Professional Ethics, Conduct and Practice) of the Malaysian Institute of Accountants (“By-Laws”) and the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (including International Independence Standards) (“IESBA Code”), and we have fulfilled our other ethical responsibilities in accordance with the By-Laws and the IESBA Code.

PricewaterhouseCoopers PLT (LLP0014401-LCA & AF 1146), Chartered Accountants, Level 10, 1 Sentral, Jalan Rakyat, Kuala Lumpur Sentral, P.O. Box 10192, 50706 Kuala Lumpur, Malaysia
T: +60 (3) 2173 1188, F: +60 (3) 2173 1288, www.pwc.com/my



**INDEPENDENT AUDITORS' REPORT
TO THE MEMBER OF GIBRALTAR BSN LIFE BERHAD (CONTINUED)
(Incorporated in Malaysia)
Registration No. 199301022976 (27714-A)**

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS (CONTINUED)

Information other than the financial statements and auditors' report thereon

The Directors of the Company are responsible for the other information. The other information comprises the Directors' Report, but does not include the financial statements of the Company and our auditors' report thereon.

Our opinion on the financial statements of the Company does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements of the Company, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements of the Company or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the financial statements

The Directors of the Company are responsible for the preparation of the financial statements of the Company that give a true and fair view in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia. The Directors are also responsible for such internal control as the Directors determine is necessary to enable the preparation of financial statements of the Company that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements of the Company, the Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements of the Company as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with approved standards on auditing in Malaysia and International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



**INDEPENDENT AUDITORS' REPORT
TO THE MEMBER OF GIBRALTAR BSN LIFE BERHAD (CONTINUED)
(Incorporated in Malaysia)
Registration No. 199301022976 (277714-A)**

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS (CONTINUED)

As part of an audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- (a) Identify and assess the risks of material misstatement of the financial statements of the Company, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- (b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- (c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- (d) Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements of the Company or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- (e) Evaluate the overall presentation, structure and content of the financial statements of the Company, including the disclosures, and whether the financial statements of the Company represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



INDEPENDENT AUDITORS' REPORT
TO THE MEMBER OF GIBRALTAR BSN LIFE BERHAD (CONTINUED)
(Incorporated in Malaysia)
Registration No. 199301022976 (277714-A)

OTHER MATTERS

This report is made solely to the member of the Company, as a body, in accordance with Section 266 of the Companies Act 2016 in Malaysia and for no other purpose. We do not assume responsibility to any other person for the content of this report.



PRICEWATERHOUSECOOPERS PLT
LLP0014401-LCA & AF 1146
Chartered Accountants



MANJIT SINGH A/L HAJANDER SINGH
02954/03/2023 J
Chartered Accountant

Kuala Lumpur
25 February 2022

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2021

	<u>Note</u>	<u>2021</u> RM'000	<u>2020</u> RM'000
ASSETS			
Properties and equipment	3	3,335	11,397
Investment property	4	5,400	5,200
Intangible assets	5	7,833	3,658
Prepaid lease property	6	-	221
Right-of-use ("ROU") assets	7	23,617	20,308
Investments	8	1,959,745	1,976,804
Held-to-maturity ("HTM") financial assets		187,685	198,091
Loans and receivables ("LAR")		60,797	60,197
Available-for-sale ("AFS") financial assets		1,062,992	1,107,105
Fair value through profit and loss ("FVTPL") financial assets		648,271	611,411
Reinsurance assets	9	12,543	12,567
Insurance receivables	10	3,558	7,048
Other receivables	11	20,354	28,036
Cash and cash equivalents		199,014	167,387
TOTAL ASSETS		2,235,399	2,232,626

The accompanying notes form an integral part of the financial statements.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2021 (CONTINUED)

	<u>Note</u>	<u>2021</u> RM'000	<u>2020</u> RM'000
EQUITY AND LIABILITIES			
Share capital	12	185,000	125,000
Retained earnings	13 (a)	100,526	67,327
AFS fair value reserves	13 (b)	14,504	35,004
Asset revaluation reserves	13 (b)	44	46
TOTAL EQUITY		<u>300,074</u>	<u>227,377</u>
Insurance contract liabilities	14	1,832,926	1,889,632
Deferred tax liabilities	15	25,507	24,104
Insurance payables	16	32,533	45,224
Tax payable		1,995	3,007
Other payables	17	22,879	21,657
Lease liabilities		19,485	21,625
TOTAL LIABILITIES		<u>1,935,325</u>	<u>2,005,249</u>
TOTAL EQUITY AND LIABILITIES		<u>2,235,399</u>	<u>2,232,626</u>

The accompanying notes form an integral part of the financial statements.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

STATEMENT OF INCOME
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

	<u>Note</u>	2021 RM'000	2020 RM'000
Operating revenue	18	<u>278,380</u>	<u>291,883</u>
Gross premiums	19 (a)	198,746	211,987
Premiums ceded to reinsurers	19 (b)	<u>(11,004)</u>	<u>(11,126)</u>
Net premiums		<u>187,742</u>	<u>200,861</u>
Investment income	20	79,634	79,896
Realised gains	21	35,742	33,957
Fair value (loss)/gain	22	(128)	54,666
Other operating income	23	<u>4,064</u>	<u>3,206</u>
Other income		<u>119,312</u>	<u>171,725</u>
Gross benefits and claims	24 (a)	(187,598)	(244,382)
Claims ceded to reinsurers	24 (b)	5,639	7,425
Gross change in contract liabilities	24 (c)	37,716	(122,307)
Change in contract liabilities ceded to reinsurers	24 (d)	<u>(262)</u>	<u>(1,096)</u>
Net insurance benefits and claims		<u>(144,505)</u>	<u>(360,360)</u>
Fee and commission expenses		(12,703)	(13,640)
Management expenses	25	<u>(95,966)</u>	<u>(99,407)</u>
Other expenses		<u>(108,669)</u>	<u>(113,047)</u>
Profit/(loss) before taxation		53,880	(100,821)
Tax (expense)/benefit	26	<u>(20,681)</u>	<u>8,144</u>
Profit/(loss) for the financial year		<u>33,199</u>	<u>(92,677)</u>
Basic/diluted profit/(loss) per share (sen)	27	<u>20.12</u>	<u>(74.14)</u>

The accompanying notes form an integral part of the financial statements.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

STATEMENT OF COMPREHENSIVE INCOME
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

	<u>Note</u>	<u>2021</u> RM'000	<u>2020</u> RM'000
Profit/(loss) for the financial year		33,199	(92,677)
Other comprehensive (loss)/income:			
<u>Item that may be subsequently reclassified</u> <u>to statement of income:</u>			
AFS fair value reserves			
- Gross fair value changes	8 (e)	(60,392)	30,158
- Taxation	15	9,628	(4,687)
Change in insurance contract liabilities arising from:			
- Fair value changes in AFS financial assets	14	32,896	(17,283)
- Taxation	14	(2,632)	1,407
		<u>(20,500)</u>	<u>9,595</u>
<u>Item that may not be subsequently reclassified</u> <u>to statement of income:</u>			
Assets revaluation reserves			
- Gross surplus from revaluation of properties and equipment		157	-
- Taxation	15	(27)	-
Change in insurance contract liabilities arising from:			
- Surplus from revaluation of properties and equipment	14	(132)	-
		<u>(2)</u>	<u>-</u>
Total comprehensive income/(loss) for the financial year		<u>12,697</u>	<u>(83,082)</u>

The accompanying notes form an integral part of the financial statements.

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021**

	Share capital RM'000	Assets revaluation reserves RM'000	Non-distributable			Distributable		Total RM'000
			AFS fair value reserves RM'000	Life non-participating surplus* RM'000	Retained earnings RM'000			
As at 1 January 2021	125,000	46	35,004	(4,007)	71,334		227,377	
Issuance of shares during the financial year	60,000	-	-	-	-	-	60,000	
Other comprehensive loss for the financial year	-	(2)	(20,500)	-	-	-	(20,502)	
Profit/(loss) for the financial year	-	-	-	45,053	(11,854)	-	33,199	
At 31 December 2021	185,000	44	14,504	41,046	59,480		300,074	
As at 1 January 2020	125,000	46	25,409	82,874	77,130		310,459	
Other comprehensive income for the financial year	-	-	9,595	-	-	-	9,595	
Loss for the financial year	-	-	-	(86,881)	(5,796)	-	(92,677)	
At 31 December 2020	125,000	46	35,004	(4,007)	71,334		227,377	

* The Life non-participating surplus amount is net of deferred tax. This amount is restricted for distribution until the actual recommended transfer from the life fund into the shareholders' fund by the Appointed Actuary in accordance with the Financial Services Act 2013 ("FSA").

The accompanying notes form an integral part of the financial statements.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

STATEMENT OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

	<u>Note</u>	<u>2021</u> RM'000	<u>2020</u> RM'000
OPERATING ACTIVITIES			
Cash used in operating activities	28	(85,853)	(61,626)
Dividend income received		14,567	11,535
Interest/profit income received		64,362	67,934
Interest paid on lease liabilities		(1,074)	(1,182)
Rental income on investment property received	20	232	259
Income tax paid		(10,688)	(7,088)
Net cash flows (used in)/generated from operating activities		<u>(18,454)</u>	<u>9,832</u>
INVESTING ACTIVITIES			
Proceeds from disposal of properties and equipment		223	-
Purchase of properties and equipment	3	(221)	(907)
Purchase of intangible assets	5	<u>(7,037)</u>	<u>(750)</u>
Net cash flows used in investing activities		<u>(7,035)</u>	<u>(1,657)</u>
FINANCING ACTIVITIES			
Repayment of lease liabilities		(2,884)	(2,778)
Issuance of shares during the financial year	12	<u>60,000</u>	-
Net cash flows generated/(used in) financing activities		<u>57,116</u>	<u>(2,778)</u>
NET INCREASE IN CASH AND CASH EQUIVALENTS			
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR		167,387	161,990
CASH AND CASH EQUIVALENTS AT END OF YEAR		<u>199,014</u>	<u>167,387</u>
Cash and cash equivalents comprise:			
Cash and bank balances		7,799	6,439
Deposits with maturity of less than 3 months - Licensed financial institutions		<u>191,215</u>	<u>160,948</u>
		<u>199,014</u>	<u>167,387</u>

The accompanying notes form an integral part of the financial statements.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

STATEMENT OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

The Company classifies the cash flows from the acquisition and disposal of financial assets as operating cash flows, as the purchases are mainly funded from the cash flows associated with the origination of insurance contracts, net the cash flows for payments of benefits and claims incurred for insurance contract, which are treated under operating activities.

(a) Analysis of changes in liabilities arising from financing activity is as follows:

	RM'000
Leases	
At 1 January 2020	23,492
Cash changes:	
Repayment	(2,778)
Interest paid	(1,182)
Non-cash changes:	
Additions (Note 7)	911
Accrued interest (Note 28)	1,182
At 31 December 2020	<u>21,625</u>
Cash changes:	
Repayment	(2,884)
Interest paid	(1,074)
Non-cash changes:	
Additions (Note 7)	803
Accrued interest (Note 28)	1,074
Lease modification	(49)
Lease termination	(10)
At 31 December 2021	<u>19,485</u>

The accompanying notes form an integral part of the financial statements.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021**

1 PRINCIPAL ACTIVITIES AND CORPORATE INFORMATION

The Company is engaged principally in the underwriting of life insurance business including investment-linked business. There has been no significant change in the nature of this activity during the financial year.

The Company is a public limited liability company, incorporated and domiciled in Malaysia. The address of the principal place of business and registered office of the Company as follows:

Level 21, Mercu 2
No 3, Jalan Bangsar
KL Eco City
59200 Kuala Lumpur

The Directors regard GH, as the immediate holding company, a company incorporated in Malaysia. The ultimate holding and penultimate holding companies are PFI and PICA. Both companies are incorporated in the USA.

The financial statements were authorised for issue by the Board in accordance with a resolution of the Directors dated 25 February 2022.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation

The financial statements of the Company for the financial year ended 31 December 2021 have been prepared in accordance with the Malaysian Financial Reporting Standards ("MFRS"), International Financial Reporting Standards ("IFRS") and comply with the requirements of the Companies Act 2016 in Malaysia.

The preparation of financial statements in conformity with MFRS requires the use of certain critical accounting estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reported period. It also requires the Directors to exercise its judgement in the process of applying the Company's accounting policies. Although these estimates and judgement are based on the Directors' best knowledge of current events and actions, actual result may differ.

The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in Note 2.27 to the financial statements.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.1 Basis of preparation (continued)

Standards, amendments to published standards and interpretations

(i) The following are accounting standards, amendments, and interpretations that have been issued by the Malaysian Accounting Standards Board ("MASB") for the financial year beginning on or after 1 January 2021 and adopted by the Company:

- Amendments to MFRS 9, MFRS 139, MFRS 7, MFRS 4 and MFRS 16 "Interest Rate Benchmark Reform-Phase 2"

The Phase 1 amendments, which was effective on 1 January 2020, provided temporary reliefs from applying specific hedge accounting requirements to relationships affected by uncertainties arising as a result of IBOR reform. The Phase 2 amendments address issues that arise from the implementation of the reforms, including the replacement of one benchmark with an alternative one.

The Phase 2 amendments provide practical expedient allowing entities to update the effective interest rate (for instruments measured at amortised cost, lessees and insurers applying the temporary exemption from MFRS 9) to account for any required changes in contractual cash flows that is a direct consequence of IBOR reform. This results in no immediate gain or loss recognised in profit or loss.

- Amendments to MFRS 16 "Covid-19-Related Rent Concessions beyond 30 June 2021" ("the 2021 amendments")

In 2020, the Company has adopted the Amendments to MFRS 16 "Covid-19 Related Rent Concessions" for the first time in its annual financial statements ended 31 December 2020.

The 2021 amendments issued on 6 April 2021 extends the applicable period of the practical expedient by one year to cover rent concessions that reduce lease payments originally due on or before 30 June 2022, provided the other conditions for applying the practical expedient are met.

The Company has early adopted the 2021 amendment for the first time in its annual financial statements ended 31 December 2021; with the date of initial application of 1 January 2021.

The detailed impacts on Covid-19 related rent concessions are disclosed in Note 2.6 to the financial statements.

Except for MFRS 16, the adoption of these amendments did not have any impact on the current period or any prior period and is not likely to affect future periods.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.1 Basis of preparation (continued)

Standards, amendments to published standards and interpretations (continued)

(ii) The following are accounting standards, amendments to standards and interpretations that have been issued by MASB but not yet effective and have not been early adopted by the Company:

(a) MFRSs, Interpretations and amendments effective from financial year beginning on or after 1 January 2022

- Annual Improvements to MFRS 9 "Fees in the '10 per cent' test for de-recognition of financial liabilities" clarifies that only fees paid or received between the borrower and the lender, including the fees paid or received on each other's behalf, are included in the cash flow of the new loan when performing the 10% test.

An entity shall apply the amendment to financial liabilities that are modified or exchanged on or after the beginning of the annual reporting period in which the entity first applies the amendment.

- Amendments to MFRS 116 "Proceeds before Intended Use" prohibit an entity from deducting from the cost of a property, plant and equipment the proceeds received from selling items produced by the property, plant and equipment before it is ready for its intended use. The sales proceeds should instead be recognised in profit or loss.

The amendments also clarify that testing whether an asset is functioning properly refers to assessing the technical and physical performance of the property, plant and equipment.

The amendments shall be applied retrospectively.

- Amendments to MFRS 3 "Reference to the Conceptual Framework" replace the reference to Framework for Preparation and Presentation of Financial Statements with 2018 Conceptual Framework. The amendments did not change the current accounting for business combinations on acquisition date. The amendments provide an exception for the recognition of liabilities and contingent liabilities should be in accordance with the principles of MFRS 137 "Provisions, contingent liabilities and contingent assets" and IC Interpretation 21 "Levies" when falls within their scope. It also clarifies that contingent assets should not be recognised at the acquisition date.

The amendments shall be applied prospectively.

- Annual Improvements to Illustrative Example accompanying MFRS 16 Leases: Lease Incentives removed the illustration on the reimbursement relating to leasehold improvements by the lessor to avoid potential confusion as the example had not explained clearly enough the conclusion as to whether the reimbursement would meet the definition of a lease incentive of MFRS 16.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.1 Basis of preparation (continued)

Standards, amendments to published standards and interpretations (continued)

(ii) The following are accounting standards, amendments to standards and interpretations that have been issued by MASB but not yet effective and have not been early adopted by the Company: (continued)

(a) MFRSs, Interpretations and amendments effective from financial year beginning on or after 1 January 2022 (continued)

- Amendments to MFRS 137 "Onerous Contracts - Cost of Fulfilling a Contract" clarify that direct costs of fulfilling a contract include both the incremental cost of fulfilling the contract as well as an allocation of other costs directly related to fulfilling contracts. The amendments also clarify that before recognising a separate provision for an onerous contract, impairment loss that has occurred on assets used in fulfilling the contract should be recognised.

The amendments shall be applied retrospectively.

(b) MFRSs, Interpretations and amendments effective from financial year beginning on or after 1 January 2023

- Amendments to MFRS 101 "Classification of liabilities as current or non-current" clarify that a liability is classified as non-current if an entity has a substantive right at the end of the reporting period to defer settlement for at least 12 months after the reporting period.

A liability is classified as current if a condition is breached at or before the reporting date and a waiver is obtained after the reporting date. A loan is classified as non-current if a covenant is breached after the reporting date.

The amendments shall be applied retrospectively.

- MFRS 17 and its amendments replace the guidance in MFRS 4 "Insurance Contracts".

MFRS 17 applies to insurance contracts issued, to all reinsurance contracts and to investment contracts with discretionary participating features if an entity also issues insurance contracts. For fixed-fee service contracts whose primary purpose is the provision of services, an entity has an accounting policy choice to account for them in accordance with either MFRS 17 or MFRS 15 "Revenue from Contracts with Customers". Insurance contracts, (other than reinsurance) where the entity is the policyholder are not within the scope of MFRS 17. Embedded derivatives and distinct investment and service components should be "unbundled" and accounted for separately in accordance with the related MFRSs. Voluntary unbundling of other components is prohibited.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.1 Basis of preparation (continued)

Standards, amendments to published standards and interpretations (continued)

(ii) The following are accounting standards, amendments to standards and interpretations that have been issued by MASB but not yet effective and have not been early adopted by the Company: (continued)

(b) MFRSs, Interpretations and amendments effective from financial year beginning on or after 1 January 2023 (continued)

MFRS 17 requires a current measurement model where estimates are remeasured at each reporting period. The measurement is based on the building blocks of discounted, probability-weighted cash flows, a risk adjustment and a contractual service margin ("CSM") representing the unearned profit of the contract. An entity has a policy choice to recognise the impact of changes in discount rates and other assumptions that related to financial risks either in profit or loss or in other comprehensive income.

Alternative measurement models are provided for the different insurance coverages:

- (a) Simplified Premium Allocation Approach if the insurance coverage period is a year or less; and
- (b) Variable Fee Approach should be applied for insurance contracts that specify a link between payments to the policyholder and the returns on the underlying items.

The requirements of MFRS 17 align the presentation of revenue with other industries. Revenue is allocated to the periods in proportion to the value of the expected coverage and other services that the insurer provides in the period, and claims are presented when incurred. Investment components are excluded from revenue and claims.

Insurers are required to disclose information about amounts, judgements and risks arising from insurance contracts.

The Company has formed a Project Steering Committee to oversee the implementation of MFRS 17. The Project Working Committee is assessing the financial and other implications that may arise during the implementation of MFRS 17.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.1 Basis of preparation (continued)

Standards, amendments to published standards and interpretations (continued)

(ii) The following are accounting standards, amendments to standards and interpretations that have been issued by MASB but not yet effective and have not been early adopted by the Company: (continued)

(b) MFRSs, Interpretations and amendments effective from financial year beginning on or after 1 January 2023 (continued)

- Amendments to MFRS 101 "Disclosure of Accounting Policies" and MFRS Practice Statement 2 "Making Materiality Judgements"

The amendments require entities to disclose material accounting policies rather than significant accounting policies in the financial statements. Entities are expected to make disclosure of accounting policies specific to the company and not generic disclosures on MFRS applications.

An accounting policy is material if, when considered together with other information included in an entity's financial statements, it can reasonably be expected to influence decisions that the users make based on those financial statements.

Also, accounting policy information is expected to be material if, without it, the users of the financial statements would be unable to understand other material information in the financial statements. Immaterial accounting policy information need not be disclosed.

MFRS Practice Statement 2 was amended to provide guidance on how to apply the concept of materiality to accounting policy disclosures.

- Amendments to MFRS 108 "Accounting Policies, Changes in Accounting Estimates and Errors" clarify that the effects of a change in an input or measurement technique used to develop an accounting estimate is a change in accounting estimate, if they do not arise from prior period errors.

The distinction is important, because changes in accounting estimates are applied prospectively to transactions, other events, or conditions from the date of that change, but changes in accounting policies are generally applied retrospectively to past transactions and other past events.

- Amendments to MFRS 112 "Deferred Tax related to Assets and Liabilities arising from a Single Transaction" clarify that the initial exemption rule does not apply to transactions where both an asset and a liability are recognised at the same time such as leases and decommissioning obligations. Accordingly, entities are required to recognise both deferred tax assets and liabilities for all deductible and taxable temporary differences arising from such transactions.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.1 Basis of preparation (continued)

Standards, amendments to published standards and interpretations (continued)

- (ii) The following are accounting standards, amendments to standards and interpretations that have been issued by MASB but not yet effective and have not been early adopted by the Company: (continued)

Other than MFRS 9 and MFRS 17, the above standards, amendments to published standards and interpretations to existing standards are not anticipated to have any significant impact on the financial statements of the Company in the year of initial application.

All other new amendments to published standards and interpretations to existing standards issued by MASB effective for financial periods subsequent to 1 January 2022 are not relevant to the Company.

2.2 Properties and equipment

Properties and equipment are initially stated at cost. Land and building are subsequently revalued, based on periodic, but at least triennial, valuations by external independent valuers, less subsequent depreciation and impairment losses. Valuations are performed with sufficient regularity to ensure that the fair value of a revalued asset does not differ materially from its carrying amount. Any accumulated depreciation at the date of revaluation is eliminated against the gross carrying amount of the asset, and the net amount is restated to the revalued amount of the asset. All other properties and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are charged to the statement of income during the financial year in which they are incurred.

The surplus arising on revaluation is credited to the revaluation reserves except that a surplus, to the extent that such surplus is related to and not greater than a deficit arising on revaluation previously recorded as an expense, is credited to statement of income. A deficit arising from revaluation is recognised as an expense except that, to the extent that such a deficit is related to a surplus which was previously recorded as a credit to the asset revaluation reserves account and which has not been subsequently reversed or utilised, it is charged directly to the revaluation reserves.

Properties and equipment are depreciated on a straight line basis to write off the cost of the assets, or their revalued amounts, to their residual values over their estimated useful lives, summarised as follows:

Buildings (For 31 December 2020)	57 - 73 years
Motor vehicles	5 years
Office equipment and computers	3 - 4 years
Furniture, fittings and renovation	5 years

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.2 Properties and equipment (continued)

Leasehold buildings are depreciated over the remaining lease term of the leasehold land on which the building resides. Residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date.

At each date of the statement of financial position, the Company assesses whether there is any indication of impairment. If such indications exist, an analysis is performed to assess whether the carrying amount of the asset is fully recoverable. A write down is made if the carrying amount exceeds the recoverable amount. See Note 2.24 to the financial statements on impairment of assets.

Gains and losses on disposal are determined by comparing proceeds with the carrying amount and are included in the statement of income. On disposal of revalued assets, the revaluation reserves relating to those assets are transferred to retained earnings and/or unallocated surplus.

2.3 Intangible assets – computer software

Acquired computer software licences are capitalised on the basis of the costs incurred to acquire and bring to use the specific software. These costs are amortised over their estimated useful lives of 5 years.

Costs associated with maintaining computer software programmes are recognised as an expense when incurred. Costs that are directly associated with identifiable and unique software products controlled by the Company, and that will probably generate economic benefits exceeding costs beyond one year, are recognised as intangible assets. Costs include employee costs incurred as a result of developing software and an appropriate portion of relevant overheads.

Computer software development costs recognised as assets are amortised using the straight line method over their estimated useful lives of 5 years.

2.4 Investment property

Investment property includes office building, is held for long term rental yields or for capital appreciation or both, and is not occupied by the Company.

Investment property is initially stated at cost and subsequently carried at fair value. Fair value is based on active market prices, adjusted, if necessary, for any difference in the nature, location or condition of the specific asset. If this information is not available, the Company uses alternative valuation methods such as recent prices on less active markets or discounted cash flow projections. The fair values of investment property is reviewed annually, and a formal valuation by an independent professional valuer is carried out once in every three years or earlier if the carrying value of the investment property differs materially from the fair value. Changes in fair values are recorded in the statement of income as part of fair value gains and losses.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.4 Investment property (continued)

On disposal of an investment property, or when it is permanently withdrawn from use and no future economic benefits are expected from its disposal, it shall be derecognised (eliminated from the statement of financial position). The difference between the net disposal proceeds and the carrying amount is recognised in the statement of income in the period of the retirement or disposal.

2.5 Prepaid lease property

Payment for rights to use land over the predetermined period is classified as prepaid lease property and is stated at cost less accumulated amortisation and accumulated impairment. The prepaid lease property are amortised on a straight line basis over the lease periods of up to 99 years.

2.6 Leases

Leases are recognised as right-of-use ("ROU") assets and a corresponding liability at the date on which the leased asset is available for use by the Company (i.e. the commencement date).

Contracts may contain both lease and non-lease components. The Company allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. However, for leases of properties for which the Company is a lessee, it has elected the practical expedient provided in MFRS 16 not to separate lease and non-lease components. Both components are accounted for as a single lease component and payments for both components are included in the measurement of lease liability.

(i) Lease term

In determining the lease term, the Company considers all facts and circumstances that create an economic incentive to exercise an extension option, or not to exercise a termination option. Extension options (or periods after termination options) are only included in the lease term if the lease is reasonably certain to be extended (or not to be terminated).

The Company reassesses the lease term upon the occurrence of a significant event or change in circumstances that is within the control of the Company and affects whether the Company is reasonably certain to exercise an option not previously included in the determination of lease term, or not to exercise an option previously included in the determination of lease term. A revision in lease term results in remeasurement of the lease liabilities.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.6 Leases (continued)

(ii) ROU assets

ROU assets are initially measured at cost comprising the following:

- The amount of the initial measurement of lease liability;
- Any lease payments made at or before the commencement date less any lease incentive received;
- Any initial direct costs; and
- Decommissioning or restoration costs.

ROU assets that are not investment properties are subsequently measured at cost, less accumulated depreciation and impairment loss (if any). The ROU assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight line basis. If the Company is reasonably certain to exercise a purchase option, the ROU asset is depreciated over the underlying asset's useful life. In addition, the ROU assets are adjusted for certain remeasurement of the lease liabilities.

Long term leasehold buildings are subsequently revalued, based on periodic, but at least triennial, valuations by external independent valuers, less subsequent depreciation and impairment losses. Valuations are performed with sufficient regularity to ensure that the fair value of a revalued asset does not differ materially from its carrying amount. Any accumulated depreciation at the date of revaluation is eliminated against the gross carrying amount of the asset, and the net amount is restated to the revalued amount of the asset.

The surplus arising on revaluation is credited to the revaluation reserves except that a surplus, to the extent that such surplus is related to and not greater than a deficit arising on revaluation previously recorded as an expense, is credited to statement of income. A deficit arising from revaluation is recognised as an expense except that, to the extent that such a deficit is related to a surplus which was previously recorded as a credit to the asset revaluation reserves account and which has not been subsequently reversed or utilised, it is charged directly to the revaluation reserves.

ROU assets are depreciated on a straight line basis to write off the cost of the assets, or their revalued amounts, to their residual values over their estimated useful lives, summarised as follows:

Long term leasehold buildings	56 - 72 years
Properties	1 - 7 years
Equipment	2 - 3 years

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.6 Leases (continued)

(iii) Lease liabilities

Lease liabilities are initially measured at the present value of the lease payments that are not paid at that date. The lease payments include the following:

- Fixed payments (including in-substance fixed payments), less any lease incentive receivable;
- Variable lease payments that are based on an index or a rate, initially measured using the index or rate as at the commencement date;
- Amounts expected to be payable by the Company under residual value guarantees;
- The exercise price of a purchase and extension options if the Company is reasonably certain to exercise that option; and
- Payments of penalties for terminating the lease, if the lease term reflects the Company exercising that option.

Lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Company, the lessee's incremental borrowing rate is used. This is the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the ROU in a similar economic environment with similar term, security and conditions.

Lease payments are allocated between principal and finance cost. The finance cost is charged to statement of income over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

Variable lease payments that depend on sales are recognised in statement of income in the period in which the condition that triggers those payments occurs.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.6 Leases (continued)

(iii) Lease liabilities (continued)

The Company presents the lease liabilities as a separate line item in the statement of financial position. Interest expense on the lease liability is presented within the management expenses in the statement of income and statement of comprehensive income.

(iv) Reassessment of lease liabilities

The Company is also exposed to potential future increases in variable lease payments that depend on an index or rate, which are not included in the lease liability until they take effect. When adjustments to lease payments based on an index or rate take effect, the lease liability is remeasured and adjusted against the ROU assets.

(v) Short term leases and leases of low value assets

Short term leases are leases with a lease term of 12 months or less. Low value assets comprise IT equipment and small items of office furniture. Payments associated with short term leases of equipment and vehicles and all leases of low value assets are recognised on a straight line basis as an expense in statement of income.

(vi) Rent concession

During the financial year, the Company elects to account for a Covid-19 related rent concession that meets all of the following conditions in the same way as they would if there were not lease modification:

- (i) the change in lease payments results in revised consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change;**
- (ii) any reduction in lease payments affects only payments due on or before 30 June 2022; and**
- (iii) there is no substantive change to other terms and conditions of the lease.**

The Company accounts for such Covid-19 related rent concession as a variable lease payment in the period(s) in which the event or condition that triggers the reduced payment occurs. The Company presents the impacts of rent concession within management expenses.

Until 31 December 2021, the accounting required by MFRS 16 for a change in lease payments, other than those arising from a change in amounts expected to be payable under residual value guarantees or in an index or rate used to determine lease payments, depends on whether that change meets the definition of a lease modification.

If a rent concession results from a lease modification, the Company accounts for the rent concession as either a new lease or as a remeasurement of an existing lease liability, depending on the criteria set in MFRS 16.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.6 Leases (continued)

(vi) Rent concession (continued)

If a rent concession does not result from a lease modification, the Company accounts for the rent concession as a variable lease payment in the period(s) in which the event or condition that triggers the reduced payment occurs.

The effect arising from these changes on the statement of income of the Company as follows:

	<u>31.12.2021</u> RM'000	<u>31.12.2020</u> RM'000
<u>Management expenses</u>		
Lease interest expenses (prior to concession)	1,075	1,251
Lease payment reduction (relief due to Covid-19 pandemic)	(1)	(69)
Lease interest expenses (after concession)	<u>1,074</u>	<u>1,182</u>

2.7 Insurance receivables

Insurance receivables are recognised when due and measured on initial recognition at the fair value of the consideration received or receivable. Subsequent to initial recognition, insurance receivables are measured at amortised cost, using the effective yield method.

If there is objective evidence that the insurance receivables are impaired, the Company reduces the carrying amount of the insurance receivable accordingly and recognises that impairment loss in statement of income. The Company gathers the objective evidence that an insurance receivable is impaired using the same process adopted for financial assets carried at amortised cost. The impairment loss is calculated under the same method used for these financial assets. These processes are described in Note 2.24 to the financial statements.

Insurance receivables are derecognised when the recognition criteria for financial assets, as described in Note 2.23 to the financial statements, have been met.

2.8 Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, balances and deposits held at call with financial institutions with maturities of three months or less that are readily convertible to known amount of cash which are subject to an insignificant risk of changes in value.

2.9 Payables

Insurance and other payables are classified as current liabilities if payment is due within one year or less.

Insurance and other payables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.10 Provisions

Provisions are recognised when the Company has a present obligation as a result of a past event and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount can be made. Provisions are reviewed at each statement of financial position date and adjusted to reflect the current best estimate.

2.11 Share capital

Proceeds from ordinary shares issued are accounted for as equity, with the nominal value of the share being separately disclosed as share capital. Costs directly attributable to the issuance of new ordinary shares are accounted for as a deduction from equity.

2.12 Contingent liabilities and contingent assets

The Company does not recognise a contingent liability but discloses its existence in the financial statements. A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by uncertain future events beyond the control of the Company or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in the extremely rare circumstance where there is a liability that cannot be recognised because it cannot be measured reliably.

A contingent asset is a possible asset that arises from past events whose existence will be confirmed by uncertain future events beyond the control of the Company. The Company does not recognise a contingent asset but discloses its existence where inflows of economic benefits are probable, but not virtually certain.

2.13 Employee benefits

(i) Short term employee benefits

Wages, salaries, paid annual leave and sick leave, bonuses and non-monetary benefits are accounted in the financial year in which the associated services are rendered by employees of the Company.

(ii) Defined contribution plans

A defined contribution plan is a pension plan under which the Company pays fixed contributions to the state pension scheme, the Employees Provident Fund ("EPF").

The Company's contributions to defined contribution plans are charged to the statement of income in the financial year to which they relate. Once the contributions have been made, the Company has no further payment obligations.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.13 Employee benefits (continued)

(iii) Share-based compensation

The Company participates in share-based compensation plans granted to certain senior management employees of the Company as consideration for services rendered.

(i) Equity-settled share-based compensation

The fair value of equity settled, share-based compensation granted to employees as at the grant date is recognised in the statement of income over the vesting periods of the grant based on the closing price of the ultimate holding company, PFI stock on grant date.

(ii) Cash-settled share-based compensation

The fair value of the employee services received in exchange for the grant of the share appreciation rights is recognised in the statement of income over the vesting periods of the grant with a corresponding increase in liabilities.

2.14 Product classification

An insurance contract is a contract under which the Company (the insurer) has accepted significant insurance risk from another party (the policyholders) by agreeing to compensate the policyholders if a specified uncertain future event (the insured event) adversely affects the policyholders. The Company defines insurance risk to be significant when the benefits payable on the occurrence of the insured event are 5% or more than the benefits payable if the insured event did not occur at any one point of the insurance contract. Based on this definition, all policy contracts issued by the Company are considered insurance contracts as at the date of this statement of financial position.

Investment contracts are those contracts that do not transfer significant insurance risk, but significant financial risk. Financial risk is the risk of a possible future change in one or more of a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of price or rate, credit rating or credit index or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract. Insurance risk is the risk other than financial risk.

Once a contract has been classified as an insurance contract, it remains an insurance contract for the remainder of its life-time, even if the insurance risk reduces significantly during this period, unless all rights and obligations are extinguished or expire. Investment contracts can, however, be reclassified as insurance contracts after inception if insurance risk becomes significant.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.14 Product classification (continued)

Insurance and investment contracts are further classified as being either with or without discretionary participation features ("DPF"). DPF is a contractual right to receive, as a supplement to guaranteed benefits, additional benefits that are:

- likely to be a significant portion of the total contractual benefits;
- whose amount or timing is contractually at the discretion of the issuer; and
- that are contractually based on the:
 - performance of a specified pool of contracts of a specified type of contract;
 - realised and/or unrealised investment returns on a specified pool of assets held by the issuer; or
 - profit or loss of the company, fund or other entity that issues the contract.

Contracts in the participating fund are classified as insurance contracts with DPF and contracts in the non-participating fund are classified as insurance contracts without DPF.

For financial options and guarantees which are not closely related to the host insurance contract and/or investment contract with DPF, bifurcation is required to measure these embedded derivatives separately at fair value through profit or loss. However, bifurcation is not required if the embedded derivative is itself an insurance contract and/or investment contract with DPF, or if the host insurance contract and/or investment contract itself is measured at fair value through profit or loss.

2.15 Reinsurance

The Company cedes insurance risk in the normal course of business for all of its businesses. Reinsurance assets represent balances due from reinsurance companies. Amounts recoverable from reinsurers are estimated in a manner consistent with the outstanding claims provision or settled claims associated with the reinsurer's policies and are in accordance with the related reinsurance contracts.

Ceded reinsurance arrangements do not relieve the Company from its obligations to policyholders. Premiums and claims are presented on a gross basis for both ceded and assumed reinsurance.

Reinsurance assets are reviewed for impairment at each reporting date or more frequently when an indication of impairment arises during the reporting period. Impairment occurs when there is objective evidence as a result of an event that occurred after initial recognition of the reinsurance asset that the Company may not receive all outstanding amounts due under the terms of the contract and the event has a reliably measurable impact on the amounts that the Company will receive from the reinsurer. The impairment loss is recorded in statement of income.

Reinsurance assets or liabilities are derecognised when the contractual rights are extinguished or expire or when the contract is transferred to another party.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.16 Life insurance contract liabilities

Life insurance contract liabilities comprise:

- (i) Actuarial liabilities
- (ii) Unallocated surplus of DPF contracts
- (iii) Claims liabilities
- (iv) Available-for-sale ("AFS") fair value reserves
- (v) Asset revaluation reserves
- (vi) Net asset value attributable to unit holders

(i) Actuarial liabilities

A liability for contractual benefits that are expected to be incurred in the future is recorded when the premiums are recognised. The valuation of life insurance contract liabilities is determined according to BNM's RBC Framework as summarised below.

Participating fund insurance contract liabilities

Participating plans are valued using a prospective actuarial valuation based on the sum of the present value of future guaranteed and appropriate level of non-guaranteed benefits, and the expected future management and distribution expenses, less the present value of future gross considerations arising from the policy discounted at the appropriate risk discount rate.

The participating life insurance liability is taken as the higher of the guaranteed benefit liabilities or the total benefit liabilities.

Non-participating fund insurance contract liabilities

The liability of non-participating life plans is valued using a prospective actuarial valuation based on the sum of the present value of future benefits, and the expected future management and distribution expenses, less the present value of future gross considerations arising from the policy discounted at the appropriate risk discount rate.

Investment-linked fund insurance contract liabilities

The liability is the sum of:

- the unit reserves, calculated as the value of the underlying assets backing the units relating to the policy; and
- the non-unit reserves are determined by projecting future cashflows to ensure that all future outflows can be met without recourse to additional finance or capital support at any future time during the duration of the investment-linked policy.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.16 Life insurance contract liabilities (continued)

(i) Actuarial liabilities (continued)

Liability adequacy test

BNM Guidelines on Financial Reporting for Insurers (BNM/RH/PD 032-13) stipulates that insurers are deemed to comply with the requirements of the liability adequacy test under MFRS 4 as long as the valuation methods used are in accordance with Appendix VI or Appendix VII of the RBC Framework for Insurers. As the Company complies with the valuation method stipulated in the RBC Framework, the Company is deemed to have complied with the liability adequacy test.

(ii) Unallocated surplus

Surplus of contracts with DPF is distributable to policyholders and shareholders in accordance with the relevant terms under the insurance contracts. The Company, however, has the discretion over the amount and timing of the distribution of these surpluses to policyholders and shareholders. Surplus of contracts without DPF is attributable wholly to the shareholders and is classified as an equity of the Company. However, the amount and timing of the distribution of surplus of contracts without DPF to the shareholders is subject to the recommendation of the Company's Appointed Actuary. Unallocated surpluses of DPF, where the amounts of surplus are yet to be allocated or distributed to either policyholders or shareholders by the end of the financial year, are held within the insurance contract liabilities.

(iii) Claims liabilities

Claims liabilities represent the amount payable under a life insurance policy in respect of claims including settlement costs, are accounted for using the case-by-case method as set out above under benefits, claims and expenses.

(iv) AFS fair value reserves

Where unrealised gains or losses arise on AFS financial assets of the life participating fund, the adjustment to the insurance contract liabilities is equal to the effect that the realisation of these gains or losses at the end of the reporting period would have on these liabilities that is recognised directly in the other comprehensive income.

(v) Asset revaluation reserves

Asset revaluation reserves represent unrealised gains arising from the revaluation of long term leasehold buildings of the Life funds. The reserves arising in DPF and non-DPF is reported as a separate component of insurance contract liabilities and equity respectively until the properties are derecognised or the properties are determined to be impaired.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.16 Life insurance contract liabilities (continued)

(v) Asset revaluation reserves (continued)

The surplus arising from the revaluation of the DPF's assets may be distributed by way of bonuses to life policyholders, subject to the limit that the amount distributed should not be more than 30% of the addition to revaluation reserves or 10% of the market value of the revalued property, whichever is lower (where applicable).

(vi) Net asset value attributable to unit holders

The unit liabilities of investment-linked policy are equal to the net asset value of the investment-linked funds.

2.17 Life insurance underwriting results

Distribution of life fund surplus to the shareholders

The surplus distributable from the life insurance fund to the shareholders is based on the surplus determined by an annual actuarial valuation of the long term liabilities to policyholders, made in accordance with the provisions of the Financial Services Act 2013 ("FSA") and related regulations by the Company's Appointed Actuary.

Gross premiums

Premium income includes premium recognised in the life funds and the investment-linked funds. Premium income of the life funds is recognised as soon as the amount of the premium can be reliably measured. First premium is recognised from inception date and subsequent premium is recognised when it is due.

At the end of the financial year, all due premiums are accounted for to the extent that they can be reliably measured.

Premium income of the investment-linked funds is in respect of the net creation of units which represents premiums paid by policyholders as payment for a new contract or subsequent payments to increase the amount of that contract. Net creation of units is recognised on a receipt basis.

Reinsurance premium

Outward reinsurance premium are recognised in the same accounting period as the original policies to which the reinsurance relates.

Commission and agency expenses

Commission and agency expenses, which are costs directly incurred in securing premium on insurance policies, net of income derived from reinsurers in the course of ceding of premium to reinsurers, are charged to statement of income in the financial year in which they are incurred.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.17 Life insurance underwriting results (continued)

Benefits, claims and expenses

Benefits and claims that are incurred during the financial year are recognised when a claimable event occurs and/or when the insurer is notified.

Recoveries on reinsurance claims are accounted for in the same financial year as the original claims are recognised.

Benefits and claims arising on life insurance policies including settlement costs, less reinsurance recoveries, are accounted for using the case basis method and for this purpose, the benefits payable under a life insurance policy are recognised as follows:

- (i) maturity or other policy benefit payments due on specified dates are treated as claims payable on the due dates; and
- (ii) death, surrender and other benefits without due dates are treated as claims payable, on the date of receipt of intimation of death of the assured or occurrence of contingency covered.

2.18 Other revenue recognition

Interest income on loans is recognised on an accrual basis except where a loan is considered non-performing, where repayments are in arrears for more than six months, in which case recognition of such interest is suspended. Subsequent to suspension, interest is recognised on the receipt basis until all arrears have been paid.

Other interest income including the amount of amortisation of premium and accretion of discount is recognised on a time proportion basis that takes into account the effective yield of the assets.

Rental income is recognised on an accrual basis except where default in payment of rent has already occurred and rent due remains outstanding for more than six months, in which case recognition of rental income is suspended. Subsequent to suspension, income is recognised on the receipt basis until all arrears have been paid.

Dividend income is recognised when the right to receive payment is established.

Profits or losses arising on disposal of investments are credited or charged to the statement of income.

2.19 Taxation

Income tax on statement of income for the financial year comprises current and deferred tax. Current tax is the expected amount of income taxes payable in respect of the taxable profit and surplus for the financial year and is measured using the tax rates that have been enacted at the reporting date.

Deferred tax is recognised in full, using the liability method, on temporary differences arising between the amounts attributed to assets and liabilities for tax purposes and their carrying amounts in the financial statements.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.19 Taxation (continued)

Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which the deductible temporary differences or unused tax losses can be utilised.

Deferred tax is determined using tax rates (and tax laws) that have been enacted or substantially enacted by the date of the statement of financial position and are expected to apply when the related deferred tax asset is realised or when the deferred tax liability is settled.

2.20 Dividends

Dividends on ordinary shares are recognised as a liability and deducted from equity when they are approved by the Company's shareholder and upon receipt of approval from BNM.

2.21 Financial Instruments

Classification, recognition and measurement of financial assets

The Company classifies its financial assets into the following categories: financial assets measured at fair value through profit or loss ("FVTPL"), held-to-maturity ("HTM") financial assets, available-for-sale ("AFS") financial assets and loans and receivables ("LAR").

The classification depends on the purpose for which the investments were acquired or originated. Management determines the classification of its investments at initial recognition and re-evaluates this at every reporting date.

(i) Financial assets measured at FVTPL

Financial assets measured at FVTPL include financial assets held for trading, derivative and those designated at fair value through statement of income at inception. Investments typically bought with the intention to sell in the near future are classified as held for trading. For investments designated at fair value through profit or loss at inception, the following criteria must be met:

- the designation eliminates or significantly reduces the inconsistent treatment that would otherwise arise from measuring the assets or liabilities or recognising gains or losses on a different basis; or
- the assets and liabilities are part of a group of financial assets, financial liabilities or both which are managed and their performance are evaluated on a fair value basis, in accordance with a documented risk management or investment strategy.

These investments are initially recorded at fair value and transaction costs are expensed in statement of income. Subsequent to initial recognition, these investments are re-measured at fair value. Fair value adjustments and realised gains and losses are recognised in statement of income.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.21 Financial instruments (continued)

Classification, recognition and measurement of financial assets (continued)

(ii) HTM financial assets

Non-derivative financial assets with fixed or determinable payments and fixed maturities are classified as HTM financial assets when the Company has the positive intent and ability to hold to maturity. These investments are initially recognised at cost, being the fair value of the consideration paid for the acquisition of the investment. After initial measurement, HTM financial assets are measured at amortised cost, using the effective yield method, less allowance for impairment. Gains and losses recognised in statement of income when the investments are derecognised or impaired, as well as through the amortisation process.

(iii) LAR

LAR are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. These investments are initially recognised at cost, being the fair value of the consideration paid for the acquisition of the investments. All transaction costs directly attributable to the acquisition are also included in the cost of the investments. After initial measurement, loans and receivables are measured at amortised cost, using the effective yield method, less allowance for impairment. Gains and losses are recognised in statement of income when the investments are derecognised or impaired, as well as through the amortisation process.

(iv) AFS financial assets

AFS financial assets are non-derivative financial assets that are designated as available-for-sale or are not classified in any of the three preceding categories. These investments are initially recognised at cost, being the fair value of the consideration paid for the acquisition of the investments. After initial measurement, AFS financial assets are remeasured at fair value.

Fair value gains and losses of these investments are reported as a separate component of equity or insurance contract liabilities until the investments are derecognised or the investments are determined to be impaired.

On derecognition or impairment, the cumulative fair value gains and losses previously reported in equity or insurance contract liabilities is transferred to statement of income.

2.22 Fair value of financial instruments

The fair value of financial instruments that are actively traded in organised financial markets is determined by reference to quoted market bid prices for assets and other prices for liabilities, at the close of business on the reporting date.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.22 Fair value of financial instruments (continued)

For unit and real estate investments trusts, fair value is determined by reference to published bid values.

For financial instruments where there is no active market, the fair value is determined by using valuation techniques. Such techniques include using recent arm's length transactions, reference to the current market value of another instrument which is substantially the same, discounted cash flow analysis and/or option pricing models making maximum use of market inputs and relying as little as possible on entity-specific inputs. For discounted cash flow techniques, estimated future cash flows are based on management's best estimates and the discount rate used is a market related rate for a similar instrument. Certain financial instruments are valued using pricing models that consider, among others factors, contractual and market prices, co-relation, time value of money, credit risk, yield curve volatility factors and/or prepayment rates of the underlying positions. The use of different pricing models and assumptions could produce materially different estimates of fair values.

The fair value of debenture securities (Malaysian Government Securities, debt securities) are measured based on the lower threshold price obtained from Bond Pricing Agency Malaysia.

The fair value of floating rate and over-night deposits with financial institutions is their carrying value i.e. the cost of the deposits/placements and accrued interest/profits. The fair value of fixed interest/yield-bearing deposit is estimated using discounted cash flow techniques. Expected cash flows are discounted at current market rates for similar instruments at the reporting date.

If the fair value cannot be measured reliably, these financial instruments are measured at cost, being the fair value of the consideration paid for the acquisition of the instrument or the amount received on issuing the financial liability. All transaction costs directly attributable to the acquisition are also included in the cost of the investment.

All financial assets, except for FVTPL, are subject to review for impairment (see Note 2.24 to the financial statements).

2.23 Derecognition of financial assets

Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or when they have been transferred and the Company has also transferred substantially all risks and rewards of ownership.

2.24 Impairment of assets

Financial assets

The Company assesses at each reporting date whether a financial asset or group financial assets is impaired. A financial asset or group financial assets is impaired only if there is objective evidence of impairment as a result of one or more events that occurred has an impact on the estimated future cash flows that can be reliably estimated.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.24 Impairment of assets

Financial assets (continued)

• Financial assets carried at amortised cost

If there is objective evidence that an impairment loss on assets carried at amortised cost has been incurred, the amount of impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flow (excluding future expected credit losses that have not been incurred) discounted at the financial asset's original effective interest rate. The carrying amount of the asset is reduced and the impairment loss is recorded in the statement of income. If in a subsequent period, the amount of the impairment loss decreases, the amount of reversal shall recognised in the statement of income.

• AFS financial assets

If an AFS financial asset is impaired, an amount comprising the difference between its cost (net of any principal repayment and amortisation) and its current fair value, less any impairment loss previously recognised in other comprehensive income, is transferred from equity or insurance contract liabilities to statement of income. Reversal of impairment loss on equity instruments classified as AFS is not recognised in statement of income. Reversal of impairment losses on debt instruments classified as AFS is reversed through statement of income if the increase in the fair value of the instruments can be objectively related to an event occurring after the impairment losses were recognised in the statement of income.

• Financial assets carried at cost

If there is objective evidence that an impairment loss has been incurred on an unquoted equity instrument carried at cost, the amount of the impairment loss is measured as the difference between the carrying amount of the financial asset and the present value of estimated future cash flows, discounted at the current market rate of return for a similar financial assets.

Non-financial assets

Assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment. Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Impairment loss is recognised for the amount by which the carrying amount of the assets exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest level for which there is separately identifiable cash flows.

Non-financial assets that had suffered impairment are reviewed for possible reversal of the impairment at each reporting date. The impairment loss is charged to statement of income unless it reverses a previous revaluation in which case it is charged to the revaluation surplus. Any subsequent increase in recoverable amount is recognised in statement of income unless it reverses an impairment loss on a revalued asset, in which case it is taken a revaluation surplus.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.25 Fair value measurement

The Company categorises its fair value measurements according to a three-level hierarchy. The hierarchy prioritises the inputs used by the Company's valuation techniques for determining the fair value of the financial instruments. A level is assigned to each fair value measurement based on the lowest level input significant to the fair value measurement in its entirety. The three-level hierarchy is defined as follows:

Level 1 – Fair value measurements that are measured by reference to published quotes prices (unadjusted) in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Valuations are based on quoted prices reflecting market transactions involving assets or liabilities identical to those being measured.

Level 2 – Fair value measurements using inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in inactive markets, inputs that are observable that are not prices (such as interest rates, credit risks, etc) and inputs that are derived from or corroborated by observable market data. Valuation techniques are based on assumptions that are supported by prices from observable current market transaction are instruments for which pricing is obtained.

Level 3 – Fair value measurements using significant non market observable inputs. These include valuations for assets and liabilities that are derived using data, some or all of which is not market observable, including assumptions about risk. Unobservable inputs are inputs not supported by market data, but which are set on the basis that they represent what is reasonable given the prevailing market conditions.

In determining the fair value of its financial instruments, the Company uses observable market data, when available, and minimises the use of unobservable inputs to the extent possible when determining fair value.

2.26 Foreign currencies

(i) Functional and presentation currency

The financial statements are presented in Ringgit Malaysia ("RM"), which is the Company's functional and presentation currency. All financial information is presented in RM and has been rounded to the nearest thousand, unless otherwise stated.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.26 Foreign currencies (continued)

(ii) Transactions and balances

Foreign currency transactions of the Company are translated into the functional currency using the exchange rates prevailing at the transaction dates. Foreign currency monetary assets and liabilities are translated at exchange rates prevailing at the statement of financial position date.

Exchange differences arising from the settlement of foreign currency transactions and from the translation of foreign currency monetary assets and liabilities are included in the statement of income.

2.27 Critical accounting estimates and judgements

Estimates and judgements are continuously evaluated by the Directors and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances.

A Critical accounting estimates and assumptions

The Company makes estimates and assumptions concerning the future. The resulting accounting will by definition rarely equal the related actual results.

To enhance the information content of the estimates, certain key variables that are anticipated to have material impact to the Company's results and financial position are tested for sensitivity to changes in the underlying parameters. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are outlined below.

Valuation of life insurance contract liabilities

The valuation of the ultimate liability arising from policy benefits made under life insurance contracts is the Company's most critical accounting estimate.

The main assumptions used relate to mortality, morbidity, expenses, persistency and discount rates. The Company bases mortality and morbidity on established industry and Malaysian tables which reflect historical experiences, adjusted when appropriate to reflect the Company's unique risk exposure, product characteristics, targets markets and own claims severity and frequency experiences.

Estimates are also made as to future investment income arising from the assets backing life insurance contracts. These estimates are based on current market return as well as expectation about future economic and financial developments.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.27 Critical accounting estimates and judgements (continued)

Estimates and judgements are continuously evaluated by the Directors and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. (continued)

A Critical accounting estimates and assumptions (continued)

The Company makes estimates and assumptions concerning the future. The resulting accounting will by definition rarely equal the related actual results.

To enhance the information content of the estimates, certain key variables that are anticipated to have material impact to the Company's results and financial position are tested for sensitivity to changes in the underlying parameters. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are outlined below. (continued)

Valuation of life insurance contract liabilities

Assumption on future expenses are based on the experience of the Company and long-term expected expenses levels. An inflation rate of 2.5% per annum is assumed over time. The Company conducts an expenses study annually. The latest study suggests that the Company is currently in an expense overrun position. Allowance is also made for payment of commission to distributors. Lapse and surrender rates are based on the Company's historical experience of lapses and surrenders.

Discount rates for non-participating policies, guaranteed benefits of participating policies and the non-unit liability of investment-linked policies are based on the yields available on MGS of the term up to 15 years. In the case of total benefits liabilities of participating policies, the discount rate is based on the historical yield and future investment outlook of the participating fund, net of tax on investment income of the life fund.

Any movement in the above key assumptions will have an effect in determining the insurance business liabilities. It should be noted that movements in these assumptions are non-linear and would vary according to the current economic assumptions.

Refer to Note 32(e)(vi) to the financial statements for the sensitivity analysis of the above mentioned key assumptions.

B Critical judgements in applying the entity's accounting policies

In determining and applying accounting policies, judgement is often required in respect of items where the choice of specific policy could materially affect the reported results and financial position of the Company. However, the Directors are of the opinion that there are currently no accounting policies, which require significant judgement to be exercised.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

3 PROPERTIES AND EQUIPMENT

<u>Cost/valuation</u>	<u>Buildings</u> RM'000	<u>Motor vehicles</u> RM'000	<u>Office equipment and computers</u> RM'000	<u>Furniture, fittings and renovation</u> RM'000	<u>Total</u> RM'000
At 1 January 2021	5,480	606	20,539	13,226	39,851
Reclassified to ROU assets (Note 7)	(5,480)	-	-	-	(5,480)
Additions	-	-	215	6	221
Disposals/write-offs	-	(592)	(8,538)	(13)	(9,143)
At 31 December 2021	-	14	12,216	13,219	25,449
<u>Accumulated depreciation</u>					
At 1 January 2021	-	318	19,283	8,853	28,454
Reclassified to ROU assets (Note 7)	-	-	-	-	-
Disposals/write-offs	-	(326)	(8,538)	(12)	(8,876)
Depreciation charge for the financial year	-	15	747	1,774	2,536
At 31 December 2021	-	7	11,492	10,615	22,114
<u>Net book value</u>					
At 31 December 2021	-	7	724	2,604	3,335

During the financial year, the Company has reclassified the long term leasehold buildings to the right-of-use assets.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

3 PROPERTIES AND EQUIPMENT (CONTINUED)

	Buildings RM'000	Motor vehicles RM'000	Office equipment and computers RM'000	Furniture, fittings and renovation RM'000	Total RM'000
<u>Cost/valuation</u>					
At 1 January 2020	5,630	606	20,167	12,993	39,396
Additions	-	-	672	235	907
Disposals	-	-	(300)	(2)	(302)
Revaluation loss recorded in statement of income (Note 28)	(150)	-	-	-	(150)
At 31 December 2020	<u>5,480</u>	<u>606</u>	<u>20,539</u>	<u>13,226</u>	<u>39,851</u>
<u>Accumulated depreciation</u>					
At 1 January 2020	-	182	18,507	7,031	25,720
Disposals	-	-	(300)	(2)	(302)
Reversal on depreciation for buildings (Note 28)	(96)	-	-	-	(96)
Depreciation charge for the financial year (Note 25)	96	136	1,076	1,824	3,132
At 31 December 2020	-	<u>318</u>	<u>19,283</u>	<u>8,853</u>	<u>28,454</u>
<u>Net book value</u>					
At 31 December 2020	<u>5,480</u>	<u>288</u>	<u>1,256</u>	<u>4,373</u>	<u>11,397</u>

In 2020, the Company had carried out a valuation on the long term leasehold buildings based on open market values of the properties on existing use basis conducted by an independent qualified valuer, Knight Frank Malaysia Sdn Bhd. The valuations of these properties were adopted by the Directors for the financial year ended 31 December 2020.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

3 PROPERTIES AND EQUIPMENT (CONTINUED)

Had the long term leasehold buildings been carried at historical cost less accumulated depreciation, the carrying amounts that would have been included in the financial statements at the end of the financial year are as follows:

	<u>2020</u> RM'000
Long term leasehold buildings	<u>4,424</u>

The unexpired lease periods for 2020 is 57 years to 73 years.

Fair value information

Fair value of long term leasehold buildings are categorised as follows:

	<u>2020</u> RM'000
Level 3:	
Melaka Branch	280
Menara Liberty Level 18	5,200
Total buildings	<u>5,480</u>

The fair value of the long term leasehold buildings as at 31 December 2020 were measured and adjusted for differences using a valuation technique based on assumption supported by prices from observable current market transactions as well as the discounted cash flows at discount rates 5.00% of the current rental income based on usual tenancy terms in open market values.

Description of valuation techniques used and key inputs to valuation on long term leasehold buildings measured at Level 3:

Valuation Technique	Unobservable Input	2020
Comparison & Investment method	Revisionary Rate	3.50% - 5.00%
	Average Rental per square feet (Reversion)	RM1.30 - RM3.70
	Discount Rate	3.50% - 5.00%
	Estimated value per square feet ("psf")	RM348 – RM555 psf over strata floor area

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

4 INVESTMENT PROPERTY

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
At 1 January	5,200	5,350
Fair value gain/(loss) (Note 22)	<u>200</u>	<u>(150)</u>
At 31 December	<u>5,400</u>	<u>5,200</u>

The following investment property is held under lease terms:

Leasehold building	<u>5,400</u>	<u>5,200</u>
--------------------	--------------	--------------

Investment property is stated at fair value, which had been determined based on valuations performed by an external independent professional valuer on 31 December 2021 and 31 December 2020. Valuation is performed on an annual basis and fair value changes are recorded in the statement of income.

Fair value information

Fair value of investment property is categorised as Level 3 as follows:

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
Investment property	<u>5,400</u>	<u>5,200</u>

The following are recognised in the statement of income in respect of investment property:

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
Gross rental income	393	395
Direct operating expenses	<u>(161)</u>	<u>(136)</u>
Net rental income (Note 20)	<u>232</u>	<u>259</u>

The fair value of the long term leasehold building was measured and adjusted for differences using a valuation technique based on assumption supported by prices from observable current market transactions as well as the discounted cash flows (at discount rates 5.00%) (2020: 5.00%) of the current rental income based on usual tenancy terms in open market values.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

4 INVESTMENT PROPERTY (CONTINUED)

Description of valuation techniques used and key inputs to valuation on investment property measured at Level 3:

Valuation Technique	Unobservable Input	2021	2020
Comparison & Investment method	Term Yield	4.75%	5.25%
	Revisionary Rate	5.00%	5.00%
	Average Rental per square feet (Term)	RM3.20	RM3.91
	Average Rental per square feet (Reversion)	RM3.70	RM3.70
	Discount Rate	5.00%	5.00%
	Estimated value per square feet	RM567 psf over strata floor area	RM555 psf over strata floor area

5 INTANGIBLE ASSETS

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
<u>Software costs</u>		
<u>Cost</u>		
At 1 January	28,826	28,993
Additions	7,037	750
Impairment	-	(917)
Write-off	(8,915)	-
At 31 December	<u>26,948</u>	<u>28,826</u>
<u>Accumulated amortisation</u>		
At 1 January	25,168	22,337
Amortisation charge for the financial year (Note 25)	2,844	3,103
Impairment	-	(272)
Write-off	(8,897)	-
At 31 December	<u>19,115</u>	<u>25,168</u>
<u>Net book value</u>		
At 31 December	<u>7,833</u>	<u>3,658</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

6 PREPAID LEASE PROPERTY

	<u>2021</u> RM'000	<u>2020</u> RM'000
<u>Cost</u>		
At 1 January	265	265
Reclassified to ROU assets	(265)	-
At 31 December	<u>-</u>	<u>265</u>
<u>Accumulated amortisation</u>		
At 1 January	44	41
Amortisation charge for the financial year (Note 25)	-	3
Reclassified to ROU assets	(44)	-
At 31 December	<u>-</u>	<u>44</u>
<u>Net book value</u>		
At 31 December	<u>-</u>	<u>221</u>

7 RIGHT-OF-USE ("ROU") ASSETS

	<u>2021</u> RM'000	<u>2020</u> RM'000
Carrying amounts of ROU asset by class of underlying assets:		
Long term leasehold buildings		
Cost	5,480	-
Revaluation loss recorded in other comprehensive income	(10)	-
Revaluation gain recorded in statement of income (Note 28)	200	-
	<u>5,670</u>	<u>-</u>
Properties	17,794	20,061
Equipment	153	247
	<u>23,617</u>	<u>20,308</u>
Addition to the ROU assets during the financial year	803	911
Depreciation charge of ROU assets by class of underlying assets (Note 28):		
Long term leasehold buildings	(95)	-
Properties	(3,232)	(3,217)
Equipment	(94)	(94)
	<u>(3,421)</u>	<u>(3,311)</u>
Reversal on accumulated depreciation on long term leasehold buildings (Note 28)	95	-
	<u>(3,326)</u>	<u>(3,311)</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

7 RIGHT-OF-USE ("ROU") ASSETS (CONTINUED)

The Company has carried out a valuation on the long term leasehold buildings based on open market values of the properties on existing use basis conducted by an independent qualified valuer, Knight Frank Malaysia Sdn Bhd. The valuations of these properties were adopted by the Directors for the financial year ended 31 December 2021.

Had the long term leasehold buildings been carried at historical cost less accumulated depreciation, the carrying amounts that would have been included in the financial statements at the end of the financial year are as follows:

	<u>2021</u> RM'000
Long term leasehold buildings	<u>4,242</u>

The long term leasehold buildings have unexpired lease periods from 56 years to 72 years.

Fair value information

Fair value of long term leasehold buildings are categorised as follows:

	<u>2021</u> RM'000
Level 3:	
Melaka Branch	270
Menara Liberty Level 18	5,400
Total buildings	<u>5,670</u>

The fair value of the long term leasehold buildings were measured and adjusted for differences using a valuation technique based on assumption supported by prices from observable current market transactions as well as the discounted cash flows at discount rates 5.00% of the current rental income based on usual tenancy terms in open market values.

Description of valuation techniques used and key inputs to valuation on long term leasehold buildings measured at Level 3:

Valuation Technique	Unobservable Input	2021
Comparison & Investment method	Revisionary Rate	3.50% - 5.00%
	Average Rental per square feet (Reversion)	RM1.30 - RM3.70
	Discount Rate	3.50% - 5.00%
	Estimated value per square feet	RM348 – RM565 psf over strata floor area

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

8 INVESTMENTS

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
Malaysian Government Securities	10,450	11,312
Malaysian government guaranteed bonds	676,726	681,464
Debt securities	590,487	640,120
Equity securities	421,170	389,582
Unit trust and property trust funds	200,115	194,129
Loans	59,650	59,070
Fixed and call deposits	1,147	1,127
	<u>1,959,745</u>	<u>1,976,804</u>
Held-to-maturity ("HTM") financial assets	187,685	198,091
Loans and receivables ("LAR")	60,797	60,197
Available-for-sale ("AFS") financial assets	1,062,992	1,107,105
Fair value through profit and loss ("FVTPL") financial assets	648,271	611,411
	<u>1,959,745</u>	<u>1,976,804</u>
The following investments mature after 12 months:		
HTM financial assets	172,606	188,005
LAR financial assets	59,650	59,070
AFS financial assets	1,038,065	1,078,342
	<u>1,270,321</u>	<u>1,325,417</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

8 INVESTMENTS (CONTINUED)

(a) HTM financial assets

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
<u>Amortised cost</u>		
Unquoted in Malaysia		
Malaysian government guaranteed bonds	10,011	10,012
Debt securities	174,447	184,779
Accrued interest	3,227	3,300
	<u>187,685</u>	<u>198,091</u>
<u>Fair value</u>		
Unquoted in Malaysia		
Malaysian government guaranteed bonds	10,257	10,864
Debt securities	183,350	202,104
Accrued interest	3,227	3,300
	<u>196,834</u>	<u>216,268</u>

(b) LAR financial assets

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
<u>Amortised cost</u>		
Fixed and call deposits	1,147	1,127
Policy loans	43,871	43,959
Accrued interest	15,779	15,111
	<u>60,797</u>	<u>60,197</u>
<u>Fair value</u>		
Fixed and call deposits	1,147	1,127
Policy loans	43,871	43,959
Accrued interest	15,779	15,111
	<u>60,797</u>	<u>60,197</u>

Fixed and call deposits of the Company have an average maturity of 22 days (2020: 19 days). The interest rate per annum of fixed deposits, that was effective as at the end of the reporting year was 1.79% per annum (2020: 1.73% per annum).

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

8 INVESTMENTS (CONTINUED)

(c) AFS financial assets

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
<u>Fair value</u>		
Unquoted in Malaysia		
Equity securities	3,345	3,282
Debt securities	378,918	417,365
Malaysian Government Securities	10,450	11,312
Malaysian government guaranteed bonds	659,480	664,621
Accrued interest	10,799	10,525
	<u>1,062,992</u>	<u>1,107,105</u>

(d) FVTPL financial assets

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
<u>Fair value</u>		
Quoted in Malaysia		
Held for trading		
Equity securities	224,975	217,999
Unit trust and property trust funds	137,217	125,499
By designation		
Equity securities	192,850	168,301
Unit trust and property trust funds	62,898	68,630
Unquoted in Malaysia		
By designation		
Debt securities	30,012	30,648
Accrued interest	319	334
	<u>648,271</u>	<u>611,411</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

8 INVESTMENTS (CONTINUED)

(e) Carrying value of financial investments

	<u>HTM</u> RM'000	<u>AFS</u> RM'000	<u>FVTPL</u> RM'000	<u>Total</u> RM'000
At 1 January 2021	198,091	1,107,105	611,411	1,916,607
Purchases	-	50,338	314,828	365,166
Maturity/proceeds from sale	(10,000)	(30,148)	(317,998)	(358,146)
Realised gains (Note 21)	-	144	35,660	35,804
Fair value (losses)/gains recorded in:				
Statement of income (Note 28)	-	(4,712)	4,384	(328)
Other comprehensive loss	-	(60,392)	-	(60,392)
(Amortisation of premium)/accretion of discount	(334)	384	-	50
Movement of investment income accrued	(72)	273	(14)	187
At 31 December 2021	<u>187,685</u>	<u>1,062,992</u>	<u>648,271</u>	<u>1,898,948</u>
At 1 January 2020	213,564	1,171,021	515,667	1,900,252
Purchases	-	70,823	401,851	472,674
Maturity/proceeds from sale	(15,000)	(166,482)	(392,862)	(574,344)
Realised gains (Note 21)	-	2,006	31,951	33,957
Fair value gains recorded in:				
Statement of income (Note 28)	-	-	54,816	54,816
Other comprehensive income	-	30,158	-	30,158
(Amortisation of premium)/accretion of discount	(323)	168	-	(155)
Movement of investment income accrued	(150)	(589)	(12)	(751)
At 31 December 2020	<u>198,091</u>	<u>1,107,105</u>	<u>611,411</u>	<u>1,916,607</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

8 INVESTMENTS (CONTINUED)

(f) Estimation of fair value

Fair value hierarchy disclosure

The following table presents the Company's assets that are measured at fair value.

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>
<u>31 December 2021</u>				
FVTPL financial assets				
Quoted in Malaysia				
Equity securities	417,825	-	-	417,825
Unit trust and property trust funds	200,115	-	-	200,115
Unquoted in Malaysia				
Debt securities	-	30,331	-	30,331
AFS financial assets				
Unquoted in Malaysia				
Equity securities	-	-	3,345	3,345
Debt securities	-	372,380	6,538	378,918
Malaysian Government Securities	-	10,450	-	10,450
Malaysian government guaranteed bonds	-	659,480	-	659,480
Accrued interest	-	10,799	-	10,799
Total assets	<u>617,940</u>	<u>1,083,440</u>	<u>9,883</u>	<u>1,711,263</u>
<u>31 December 2020</u>				
FVTPL financial assets				
Quoted in Malaysia				
Equity securities	386,300	-	-	386,300
Unit trust and property trust funds	194,129	-	-	194,129
Unquoted in Malaysia				
Debt securities	-	30,982	-	30,982
AFS financial assets				
Unquoted in Malaysia				
Equity securities	-	-	3,282	3,282
Debt securities	-	406,780	10,585	417,365
Malaysian Government Securities	-	11,312	-	11,312
Malaysian government guaranteed bonds	-	664,621	-	664,621
Accrued interest	-	10,525	-	10,525
Total assets	<u>580,429</u>	<u>1,124,220</u>	<u>13,867</u>	<u>1,718,516</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

8 INVESTMENTS (CONTINUED)

(f) Estimation of fair value (continued)

Fair value hierarchy disclosure (continued)

	<u>2021</u> RM'000	<u>2020</u> RM'000
<u>Level 3</u>		
At 1 January	13,867	13,353
Fair value gains	728	514
Impairment of financial assets (Note 22):		
AFS debt securities	(4,700)	-
Unquoted shares	(12)	-
At 31 December	<u>9,883</u>	<u>13,867</u>

As observable prices are not available for these securities, the Directors have determined the fair values based on discounted cash flows and the binding bid price as quoted by the issuer. The valuations are not sensitive to a change in unobservable inputs.

Level 3 valuations are reviewed on an annual basis by the Company's management. The management considers the appropriateness of the valuation model inputs, as well as the valuation result using the valuation method and techniques generally recognised as standard within industry.

9 REINSURANCE ASSETS

	<u>2021</u> RM'000	<u>2020</u> RM'000
Reinsurance of insurance contracts liabilities (Note 14)		
Claims liabilities	6,487	6,249
Actuarial liabilities	6,056	6,318
	<u>12,543</u>	<u>12,567</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

10 INSURANCE RECEIVABLES

	<u>2021</u> RM'000	<u>2020</u> RM'000
Outstanding premiums including agents, brokers and co-insurers balances	2,756	4,036
Amounts due from reinsurers	<u>802</u>	<u>3,012</u>
	<u>3,558</u>	<u>7,048</u>
<u>Impairment movement</u>		
At 1 January	-	(6)
Charge for financial year	<u>-</u>	<u>6</u>
At 31 December	<u>-</u>	<u>-</u>

The Company does not off-set its insurance receivables against insurance payables. The Company does not have any financial instruments subject to an enforceable master netting arrangement or financial collateral (pledged or received) as at 31 December 2021 (2020: RM nil).

11 OTHER RECEIVABLES

	<u>2021</u> RM'000	<u>2020</u> RM'000
Income due and accrued	675	1,106
Receivable from fund managers and brokers	18,417	22,513
Other receivables, deposits and prepayments	<u>1,262</u>	<u>4,417</u>
	<u>20,354</u>	<u>28,036</u>
Receivables after 12 months	<u>244</u>	<u>268</u>

The Company does not off-set its other receivables against other payables. The Company does not have any financial instruments subject to an enforceable master netting arrangement or financial collateral (pledged or received) as at 31 December 2021 (2020: RM nil).

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

12 SHARE CAPITAL

	2021		2020	
	Number of shares '000	Amount RM'000	Number of shares '000	Amount RM'000
Issued and fully paid ordinary shares:				
At the beginning of the financial year	125,000	125,000	125,000	125,000
Issued during the financial year	60,000	60,000	-	-
At the end of financial year	<u>185,000</u>	<u>185,000</u>	<u>125,000</u>	<u>125,000</u>

During the financial year, the Company increased its issued and fully paid-up capital to RM185,000,000 by the allotment of RM60,000,000 (2020: nil) new ordinary shares on 5 May 2021.

13 RESERVES

(a) Retained earnings

The non-distributable retained earnings represent the unallocated surplus from the Non-Participating Fund. In accordance with Section 83 of the FSA, the unallocated surplus is only available for distribution to the shareholders upon approval/recommendation by the Appointed Actuary.

Pursuant to the single tier system, any dividends distributed by the Company will be exempted from tax in the hand of shareholders. The Company shall not be entitled to deduct on dividend paid, credited or distributed to shareholders.

The Company may distribute single tier exempt dividend to its shareholders out of its retained earnings. Pursuant to Section 51(1) of the FSA, the Company is required to obtain BNM's written approval prior to declaring or paying any dividend with effect from the financial year beginning 1 December 2013. Pursuant to the RBC Framework for Insurers, the Company shall not pay dividends if its Capital Adequacy position is less than its internal target capital level or if the payment of dividend would impair its Capital Adequacy Ratio ("CAR") position to below its internal target.

(b) Other reserves

Other reserves consist of AFS fair value reserves and asset revaluation reserve.

The AFS fair value reserves of the Company represent the fair value gains or losses of the AFS financial assets, net of deferred tax, of the Life Non-Participating and Shareholders' funds.

The asset revaluation reserve represents the revaluation surplus of self-occupied properties.

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

14 INSURANCE CONTRACT LIABILITIES

	2021		2020		
	Gross RM'000	Re- insurance RM'000	Net RM'000	Re- insurance RM'000	Net RM'000
Benefits and claims liabilities	199,911	(6,487)	193,424	(6,249)	182,521
Actuarial liabilities	1,293,957	(6,056)	1,287,901	(6,318)	1,367,147
Unallocated surplus	24,655	-	24,655	-	2,465
AFS fair value reserves	25,391	-	25,391	-	55,655
Asset revaluation reserves	347	-	347	-	215
Net asset value attributable to unit holders	288,665	-	288,665	-	269,062
	<u>1,832,926</u>	<u>(12,543)</u>	<u>1,820,383</u>	<u>(12,567)</u>	<u>1,877,065</u>

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

14 **INSURANCE CONTRACT LIABILITIES (CONTINUED)**

	Gross		Reinsurance		Net RM'000
	With DPF	Without DPF	With DPF	Without DPF	
	RM'000	RM'000	RM'000	RM'000	
As at 1 January 2021	937,385	952,247	(216)	(12,351)	1,877,065
Change in life insurance fund contract liabilities					
Due to assumptions change					
Mortality/morbidity	2,177	(5,721)	-	-	(3,544)
Lapse/withdrawal	280	2,638	-	-	2,918
Interest and bonus rate	(5,530)	(41,024)	-	-	(46,554)
Others	16	(86)	-	-	(70)
Projected cash flow for inforce policies					
Premium	52,824	65,507	-	-	118,331
Investment return	36,204	8,927	-	-	45,131
Benefits	(94,720)	(68,644)	-	-	(163,364)
Expenses/commission	(7,980)	(17,477)	-	-	(25,457)
Variance on inforce policies	18,477	21,643	-	-	40,120
New business reserves	174	(5,279)	-	-	(5,105)
Others	(19,157)	(22,757)	(3)	265	(41,652)
Benefits and claims experience variation	8,013	3,128	27	(265)	10,903
Net asset value attributable to unit holders	-	19,603	-	-	19,603
AFS fair value reserves	(32,896)	-	-	-	(32,896)
Assets revaluation reserves	132	-	-	-	132
Unallocated surplus	22,190	-	-	-	22,190
Deferred tax effects:					
AFS fair value reserves	2,632	-	-	-	2,632
At 31 December 2021	920,221	912,705	(192)	(12,351)	1,820,383

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

14 **INSURANCE CONTRACT LIABILITIES (CONTINUED)**

	As at 1 January 2020		Gross		Reinsurance		Net RM'000
	With DPF RM'000	Without DPF RM'000	Total RM'000	With DPF RM'000	Without DPF RM'000	Total RM'000	
As at 1 January 2020	950,664	797,376	1,748,040	(164)	(11,383)	(11,547)	1,736,493
Change in life insurance fund contract liabilities							
Due to assumptions change							
Mortality/morbidity	(1,577)	1,814	237	-	-	-	237
Lapse/withdrawal	-	301	301	-	-	-	301
Interest and bonus rate	(1,409)	27,396	25,987	-	-	-	25,987
Others	(1,048)	11,878	10,830	-	-	-	10,830
Projected cash flow for inforce policies							
Premium	60,079	69,721	129,800	-	-	-	129,800
Investment return	36,103	8,996	45,099	-	-	-	45,099
Benefits	(163,583)	(72,196)	(235,779)	-	-	-	(235,779)
Expenses/commission	(8,585)	(18,205)	(26,790)	-	-	-	(26,790)
Variance on inforce policies	26,007	16,132	42,139	-	-	-	42,139
New business reserves	240	1,691	1,931	-	-	-	1,931
Others	18,240	52,706	70,946	(2)	1,098	1,096	72,042
Benefits and claims experience variation	2,008	1,326	3,334	(50)	(2,066)	(2,116)	1,218
Net asset value attributable to unit holders	-	53,311	53,311	-	-	-	53,311
AFS fair value reserves	17,283	-	17,283	-	-	-	17,283
Assets revaluation reserves	75	-	75	-	-	-	75
Unallocated surplus	4,295	-	4,295	-	-	-	4,295
Deferred tax effects:							
AFS fair value reserves	(1,407)	-	(1,407)	-	-	-	(1,407)
At 31 December 2020	937,385	952,247	1,889,632	(216)	(12,351)	(12,567)	1,877,065

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

15 DEFERRED TAX LIABILITIES

	<u>2021</u> RM'000	<u>2020</u> RM'000
At 1 January	24,104	35,479
Recognised in:		
Statement of income (Note 26)	11,004	(16,062)
Other comprehensive income		
Deferred tax on AFS fair value reserves	(9,628)	4,687
Deferred tax on assets revaluation reserves	27	-
At 31 December	<u>25,507</u>	<u>24,104</u>

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when the deferred taxes relate to the same tax authority.

	<u>2021</u> RM'000	<u>2020</u> RM'000
Presented after appropriate offsetting as follows:		
Deferred tax assets	(887)	(589)
Deferred tax liabilities	26,394	24,693
	<u>25,507</u>	<u>24,104</u>
Current	262	247
Non-current	25,245	23,857
	<u>25,507</u>	<u>24,104</u>

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

15 DEFERRED TAX LIABILITIES (CONTINUED)

The components and movements of deferred tax assets during the year prior to offsetting are as follows:

	Fair value of investment assets RM'000	Accelerated capital allowance on properties and equipment RM'000	Amortisation of premium on investment RM'000	Total RM'000
<u>Deferred tax assets</u>				
At 1 January 2020	(323)	(194)	(138)	(655)
Recognised in:				
Statement of income	63	25	(25)	63
Other comprehensive income	3	-	-	3
At 31 December 2020	(257)	(169)	(163)	(589)
Recognised in:				
Statement of income	(148)	-	(50)	(198)
Other comprehensive income	(100)	-	-	(100)
At 31 December 2021	(505)	(169)	(213)	(887)

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

15 DEFERRED TAX LIABILITIES (CONTINUED)

The components and movements of deferred tax liabilities during the financial year prior to offsetting are as follows:

	Fair value of investment assets RM'000	Loan and receivable RM'000	Fair value of investment property RM'000	Fair value of ROU assets – long term leasehold buildings RM'000	Accelerated capital allowance on properties and equipment RM'000	Accretion of discounts on investment RM'000	Unallocated surplus RM'000	Total RM'000
<u>Deferred tax liabilities</u>								
At 1 January 2020	16,068	(77)	140	-	234	328	19,441	36,134
Recognised in:								
Statement of income	4,368	-	(12)	-	(184)	82	(20,379)	(16,125)
Other comprehensive income	4,684	-	-	-	-	-	-	4,684
At 31 December 2020	25,120	(77)	128	-	50	410	(938)	24,693
Recognised in:								
Statement of income	326	78	16	-	149	65	10,568	11,202
Other comprehensive income	(9,528)	-	-	27	-	-	-	(9,501)
At 31 December 2021	15,918	1	144	27	199	475	9,630	26,394

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

16 INSURANCE PAYABLES

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
Amount due to insureds	22,720	35,069
Amount owing to client and intermediaries	4,120	4,569
Amount owing to reinsurers and cedants	5,693	5,586
	<u>32,533</u>	<u>45,224</u>

The carrying amounts disclosed above approximate fair value at the statement of financial position date.

The Company does not off-set its insurance payables against insurance receivables. The Company does not have any financial instruments subject to an enforceable master netting arrangement or financial collateral (pledged or received) as at 31 December 2021 (2020: RM nil).

17 OTHER PAYABLES

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
Accrued expenses	9,011	6,107
Provision for bonus	8,581	8,459
Unclaimed monies	496	710
Payable to investment brokers	113	838
Agency related expenses accrued	1,235	560
Marketing related expenses accrued	-	66
Other payables and accruals	3,374	4,891
Director related expenses accrued	69	26
	<u>22,879</u>	<u>21,657</u>

The carrying amounts disclosed above approximate fair value at the statement of financial position date.

The Company does not off-set its other payables against other receivables. The Company does not have any financial instruments subject to an enforceable master netting arrangement or financial collateral (pledged or received) as at 31 December 2021 (2020: RM nil).

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

18 OPERATING REVENUE

	<u>2021</u> RM'000	<u>2020</u> RM'000
Gross premiums (Note 19)	198,746	211,987
Investment income (Note 20)	79,634	79,896
	<u>278,380</u>	<u>291,883</u>

19 NET PREMIUMS

	<u>2021</u> RM'000	<u>2020</u> RM'000
(a) Gross premiums: Insurance contracts	198,746	211,987
(b) Premiums ceded to reinsurers: Insurance contracts	(11,004)	(11,126)
Net premiums	<u>187,742</u>	<u>200,861</u>

20 INVESTMENT INCOME

	<u>2021</u> RM'000	<u>2020</u> RM'000
Rental income from investment properties (Note 4)	232	259
FVTPL financial assets - held for trading purposes:		
Interest	1,793	2,009
Dividend/distribution income		
Equity securities quoted in Malaysia	11,572	8,965
Equity securities unquoted in Malaysia	2,565	3,200
HTM financial assets:		
Interest	9,477	10,241
Accretion of discounts net of amortisation of premiums	(334)	(323)
AFS financial assets:		
Interest	46,825	49,015
Accretion of discounts net of amortisation of premiums	384	168
LAR:		
Interest from loan	3,617	3,184
Interest from fixed and called deposits	3,503	3,178
	<u>79,634</u>	<u>79,896</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

21 REALISED GAINS

	<u>2021</u> RM'000	<u>2020</u> RM'000
Properties and equipment	(62)	-
Financial assets at FVTPL - held for trading purposes:		
Equity securities and unit trusts quoted in Malaysia	35,920	31,804
Debt securities	(260)	147
HTM financial assets:		
Debt securities unquoted in Malaysia	-	-
AFS financial assets:		
Debt securities	144	2,006
	<u>35,804</u>	<u>33,957</u>
Total realised gains	<u>35,742</u>	<u>33,957</u>

22 FAIR VALUE (LOSS)/GAIN

	<u>2021</u> RM'000	<u>2020</u> RM'000
Investment property (Note 4)	200	(150)
FVTPL investments – held for trading purposes	(1,490)	15,646
FVTPL investments – designated		
Unquoted in Malaysia		
Debt securities	(1,014)	444
Quoted in Malaysia		
Equity securities	9,782	22,699
Unquoted in Malaysia		
Unit trust and property trust funds	(2,894)	16,027
Impairment of AFS debt securities (Note 8)	(4,700)	-
Impairment of unquoted securities (Note 8)	(12)	-
	<u>(128)</u>	<u>54,666</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

23 OTHER OPERATING INCOME

	<u>2021</u> RM'000	<u>2020</u> RM'000
Policyholder administration and investment management services	4,112	3,020
Other (expense)/income	(48)	186
	<u>4,064</u>	<u>3,206</u>

24 NET INSURANCE BENEFITS AND CLAIMS

	<u>2021</u> RM'000	<u>2020</u> RM'000
(a) Gross benefits and claims:		
Insurance contracts		
• Death	(21,819)	(22,876)
• Maturity	(36,237)	(95,824)
• Surrender	(79,197)	(73,460)
• Others	(50,345)	(52,222)
	<u>(187,598)</u>	<u>(244,382)</u>
(b) Claims ceded to reinsurers:		
Insurance contracts	<u>5,639</u>	<u>7,425</u>
(c) Gross change in contract liabilities:		
Insurance contracts	<u>37,716</u>	<u>(122,307)</u>
(d) Change in contract liabilities ceded to reinsurers:		
Insurance contracts	<u>(262)</u>	<u>(1,096)</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

25 MANAGEMENT EXPENSES

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
Employee benefits expense (Note 25 (a))	51,239	56,549
Directors' remuneration:		
- current year (Note 25 (d))	915	670
*Auditors' remuneration:		
- statutory audit services	266	274
- other services	-	9
Depreciation of properties and equipment (Note 3)	2,536	3,132
Depreciation of right-of-use assets (Note 7)	3,421	3,311
Amortisation of intangible assets (Note 5)	2,844	3,103
Amortisation of prepaid lease property (Note 6)	-	3
Training expenses	214	(76)
Printing and stationery	285	267
Postage, telephone and telefax	835	1,012
EDP expenses	7,185	6,127
Investment expenses	9,142	5,680
Write-off of bad debts	26	306
Administration and general expenses	17,058	19,040
	<u>95,966</u>	<u>99,407</u>

* There was no indemnity given or insurance effected for the auditors of the Company during the financial year.

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
(a) Employee benefits expense		
Wages, salaries and bonuses	40,657	44,805
Contributions to social security ("SOCSO")	251	274
Contributions to EPF	6,546	6,454
Share based payment	95	446
Other benefits	3,690	4,570
Total employee benefits expenses	<u>51,239</u>	<u>56,549</u>

The remuneration, including benefits-in-kind, attributable to the Chief Executive Officer of the Company during the financial year amounted to RM 2,732,000 (2020: RM 3,406,000) as disclosed in Note 25 (b) to the financial statements.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

25 MANAGEMENT EXPENSES (CONTINUED)

(b) CEO remuneration

The details of remuneration, attributable to the CEO of the Company are as follow:

(i) CEO for the period up to 23 January 2021

	<u>2021</u> RM'000	<u>2020</u> RM'000
Salary	94	1,536
Bonus	1,053	1,110
Benefits-in-kind	2	35
Retirement benefit	11	173
Others	358	552
	<u>1,518</u>	<u>3,406</u>

(ii) CEO for the period beginning 24 January 2021

	<u>2021</u> RM'000	<u>2020</u> RM'000
Salary	776	-
Bonus	189	-
Benefits-in-kind	60	-
Retirement benefit	168	-
Others	21	-
	<u>1,214</u>	<u>-</u>
Total	<u>2,732</u>	<u>3,406</u>

(c) Compensation of key management personnel

The compensation of the key management personnel excluding the CEO as disclosed in Note 25 (b) to the financial statements is as follows:

	<u>2021</u> RM'000	<u>2020</u> RM'000
Short term employee benefits	4,319	5,394
Defined contribution plan	594	720
	<u>4,913</u>	<u>6,114</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

25 MANAGEMENT EXPENSES (CONTINUED)

(d) Directors' remuneration

	<u>2021</u> RM'000	<u>2020</u> RM'000
<u>Director fees</u>		
Dato' Haji Kamil Khalid Ariff	187	156
Dato' Danapalan A/L T.P. Vinggrasalam	153	128
Ramesh Pillai	148	123
Oh Teik Tatt	153	128
Yu Chwee Kum, Rosalind	40	-
	<u>681</u>	<u>535</u>
<u>Director allowances</u>		
Dato' Haji Kamil Khalid Ariff	58	35
Dato' Danapalan A/L T.P. Vinggrasalam	55	33
Ramesh Pillai	55	34
Oh Teik Tatt	57	33
Yu Chwee Kum, Rosalind	9	-
	<u>234</u>	<u>135</u>
	<u>915</u>	<u>670</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

26 TAXATION

	Life funds RM'000	Shareholders' fund RM'000	Total RM'000
2021			
Current tax	6,324	3,353	9,677
Deferred tax (Note 15)	691	10,313	11,004
Tax expense/(benefit)	7,015	13,666	20,681
Current tax			
Current financial year	7,556	296	7,852
(Over)/under provision in prior financial years	(1,232)	3,057	1,825
	<u>6,324</u>	<u>3,353</u>	<u>9,677</u>
Deferred tax			
Origination and reversal of temporary differences	691	10,313	11,004
	<u>7,015</u>	<u>13,666</u>	<u>20,681</u>
2020			
Current tax	7,621	297	7,918
Deferred tax (Note 15)	4,301	(20,363)	(16,062)
Tax expense/(benefit)	11,922	(20,066)	(8,144)
Current tax			
Current financial year	7,575	297	7,872
Under provision in prior financial years	46	-	46
	<u>7,621</u>	<u>297</u>	<u>7,918</u>
Deferred tax			
Origination and reversal of temporary differences	4,301	(20,363)	(16,062)
	<u>11,922</u>	<u>(20,066)</u>	<u>(8,144)</u>

Domestic income tax for shareholders' fund is calculated at the Malaysian statutory rate of 24% (2020: 24%) of the estimated assessable profit for the financial year. The amount of tax charged on the life fund is based on the method prescribed under the Income Tax Act 1967 for life insurance business. The statutory tax rate for the life insurance business is 8%.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

26 **TAXATION (CONTINUED)**

A reconciliation of income tax expenses applicable to profit/loss before taxation at the statutory income tax rate to income tax expense at the effective income tax rate of the Company is as follows:

	<u>2021</u> RM'000	<u>2020</u> RM'000
Profit/(loss) before taxation	53,880	(100,821)
Taxation at Malaysian statutory tax rate of 24% (2020: 24%)	12,931	(24,197)
Effect of difference in tax rate	(4,554)	(4,796)
Income not subject to tax	(45,890)	(27,865)
Expenses not deductible for tax purpose	51,616	41,578
Tax impact on investment income attributable to policyholders and unit holders	4,753	7,090
Under provision in prior financial years	1,825	46
Tax expense/(benefit) for the financial year	<u>20,681</u>	<u>(8,144)</u>

27 **PROFIT/(LOSS) PER SHARE**

The basic earnings per ordinary share has been calculated by dividing the net profit/(loss) for the financial year of the Company over the weighted average number of shares of the Company in issue during the financial year.

Diluted earnings per share are not presented as there were no dilutive potential ordinary shares as at the date of the statement of financial position.

	<u>2021</u> RM'000	<u>2020</u> RM'000
Profit/(loss) for the financial year	<u>33,199</u>	<u>(92,677)</u>
Weighted average number of shares in issue	<u>165,000</u>	<u>125,000</u>
Basic/diluted profit/(loss) per share (sen)	<u>20.12</u>	<u>(74.14)</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

28 CASH FLOWS

	<u>Note</u>	<u>2021</u> RM'000	<u>2020</u> RM'000
Profit/(loss) for the financial year		33,199	(92,677)
Tax expense/(benefit)	26	20,681	(8,144)
Investment income	20	(79,634)	(79,896)
Realised gains recorded in statement of income:			
- Investment assets	21	(35,742)	(33,957)
Fair value (gain)/loss recorded in statement of income:			
- Investment property	4	(200)	150
- Investment assets	8 (e)	328	(54,816)
Purchases of FVTPL financial assets	8 (e)	(314,828)	(401,851)
Maturity/proceeds from sale of FVTPL financial assets	8 (e)	317,998	392,862
Purchases of AFS financial assets	8 (e)	(50,338)	(70,823)
Maturity/proceeds from sale of AFS financial assets	8 (e)	30,148	166,482
Maturity of HTM financial assets	8 (e)	10,000	15,000
Decrease in LAR		88	1,006
Increase in fixed and call deposit		(21)	(34)
Non-cash items:			
Depreciation of properties and equipment	3	2,536	3,132
Depreciation of right-of-use assets	7	3,421	3,311
Amortisation of intangible assets	5	2,844	3,103
Amortisation of prepaid lease property	6	-	3
Reversal of depreciation for buildings	3	-	(96)
Reversal on accumulated depreciation on long term leasehold buildings	7	(95)	-
Interest on lease liabilities		1,074	1,182
Loss on property equipment	3	-	150
Gain on right-of-use assets	7	(200)	-
Intangible assets impairment	5	-	645
Changes in working capital:			
Decrease/(increase) in reinsurance assets		24	(1,020)
Decrease in insurance receivables		3,490	1,505
(Increase)/decrease in other receivables		(48,087)	99,849
(Decrease)/increase in insurance contract liabilities		(2,296)	113,874
Decrease in insurance payables		(12,691)	(8,770)
Increase/(decrease) in other payables		32,448	(111,796)
Cash used in operating activities		<u>(85,853)</u>	<u>(61,626)</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

29 CAPITAL COMMITMENTS

As of 31 December 2021, capital expenditure approved by Directors but not provided for in the financial statements are as follows:

	<u>2021</u> RM'000	<u>2020</u> RM'000
Authorised and contracted but not provided for:		
Computer hardware and software	1,445	2,796
Properties and equipment	-	2
	<u>1,445</u>	<u>2,798</u>
Approved and not contracted for:		
Properties and equipment	-	23
	<u>-</u>	<u>23</u>

30 REGULATORY CAPITAL REQUIREMENTS

The capital structure of the Company as at 31 December 2021, as prescribed under the RBC Framework is provided below:

	<u>2021</u> RM'000	<u>2020</u> RM'000
<u>Eligible Tier 1 Capital</u>		
Share capital (paid up)	185,000	125,000
Valuation surplus, retained earnings and other capital available	<u>211,100</u>	<u>143,974</u>
	<u>396,100</u>	<u>268,974</u>
<u>Tier 2 Capital</u>		
Eligible Tier 2 Capital	43,723	99,054
Amount deducted from Capital	<u>(9,471)</u>	<u>(8,106)</u>
	<u>34,252</u>	<u>90,948</u>
 Total Capital Available	 <u>430,352</u>	 <u>359,922</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

31 RELATED PARTY DISCLOSURES

In the normal course of business, the Company undertakes various transactions with other companies deemed related by virtue of being subsidiaries and associated companies of PFI and of BSN. The transactions were entered into between the Company and related parties based on agreed terms and conditions.

(a) Related parties and relationship

The related parties of, and their relationship, with the Company are as follows:

<u>Related companies</u>	<u>Country of Incorporation</u>	<u>Relationship</u>
Prudential Financial, Inc. ("PFI")	United States of America	Ultimate holding company
The Prudential Insurance Company of America ("PICA")	United States of America	Penultimate holding company
Bank Simpanan Nasional ("BSN")	Malaysia	Substantial shareholder
Gibraltar BSN Holdings Sdn. Bhd. ("GH")	Malaysia	Immediate holding company
<u>Affiliated company</u>		
Key management personnel	Malaysia	Key management personnel are those people defined as having authority and responsibility for planning, directing and controlling the activities of the Company, either directly or indirectly.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

31 RELATED PARTY DISCLOSURES (CONTINUED)

(b) Related party balances

The significant related party balances as at end of the financial year are as follows:

	<u>Note</u>	<u>2021</u> RM'000	<u>2020</u> RM'000
Included in cash and cash equivalents and investment:	8		
Bank balances, fixed and call deposits placed with			
• BSN		32,834	29,470
Interest income receivable from			
• BSN		85	18
Included in other payables:	17		
Outstanding general and administrative expenses due to			
• BSN		(2,580)	(2,864)
• PFI		(540)	(1,830)

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

31 RELATED PARTY DISCLOSURES (CONTINUED)

(c) Related party transactions

The significant related party transactions of the Company with related parties during the financial year are as follows:

	<u>2021</u>	<u>2020</u>
	RM'000	RM'000
Commission expenses paid/payable to:		
• BSN	(2,799)	(3,429)
Interest income received/receivable from:		
• BSN	655	650
General and administrative expenses paid/payable to:		
• PFI	(1,161)	(924)
• BSN	(4,375)	(4,676)

(d) Key management personnel

Identified key management personnel received remuneration for services rendered during the financial year. The total compensation paid to the Company's key management personnel as disclosed in Note 25 to the financial statements.

32 RISK MANAGEMENT FRAMEWORK

(a) Overview of the Enterprise Risk Management Framework

The Enterprise Risk Management Framework ("the Framework") sets out the governance structure in place to support implementation of a structured Risk Management process and to embed the risk management culture across the Company. It seeks to promote principles of sound corporate governance and effective management of risk to ensure that the risk-taking activities are aligned with the Company's objectives and risk appetite.

The Framework ensures that all key risks are identified, adequately assessed, treated, monitored, controlled and reported to the relevant stakeholders on a timely basis. Apart from safeguarding the Company financial strength and providing a strong platform for sustainable growth, it enables the Company to fulfill its obligations due to policyholders, shareholders, stakeholders, and at the same time, meeting the expectation of the Regulator.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(b) Enterprise Risk Management Principles

Risk is defined as the possibility that an event may occur and adversely impact the achievement of the Company's mission or business objectives. Proactive management of risk is an integral part of our business and the main objective of having the Framework in place is to ensure that all key risks are appropriately managed.

Broadly, the Framework classifies management of risks into seven broad categories and these are:

1. Market risk
2. Credit risk
3. Liquidity risk
4. Insurance risk
5. Operational risk
6. Technology & Cyber risk
7. Strategic risk

During the course of business, decisions taken and/or functions performed may expose the Company to one or more categories of risks. In order to strike a right balance of risks versus returns, these risks are managed to within acceptable limits, either by the Business and/or operational heads or established committees. This is possible owing to the proper Risk Governance structure being put in place within the Company. To this end, each of the committees have been set up and governed under clearly defined Terms of Reference, roles and responsibilities and level of delegated authorities, to ensure that the committees perform as intended.

(c) Capital management

The Company's capital management policy is to ensure that scenarios under which the possibility of future shortage of capital are accurately and timely identified and reported so that immediate remedial actions can be taken, utilise capital efficiently given limited resources for life insurers, achieve optimal balance in the management of risk, return, capital requirement as well as capital availability, and reduce the capital requirement by putting in place proper controls, risk management processes and procedures to minimise and reduce unwanted surplus /losses.

Regulatory capital

The Company is required to comply with the RBC Framework which is the capital adequacy framework for all insurers licensed under the FSA. The CAR is calculated as follows:

$$\text{CAR} = \frac{\text{Total Capital Available ("TCA")}}{\text{Total Capital Required ("TCR")}} \times 100\%$$

The Company has met all the regulatory requirements and operates at capital level above Individual Target Capital Level throughout the financial year.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(d) Governance framework

The Company's Board of Directors retains the overall risk management responsibilities in accordance with BNM's Corporate Governance (BNM/RH/PD 029-9) and Guidelines on Risk Governance (BNM/RH/GL 013-5).

Whilst the Board still retains ultimate responsibilities for risk management and for determining the appropriate level of risk appetite, a Board Risk Management Committee consisting of non-executive directors has been established to assist the Board in overseeing the risk management strategies and provide an independent risk management reporting line for the Company.

An Enterprise Risk Management Committee is also established at Senior Management level and shall meet at least four times a year, to review the Company's risk exposure and to raise and discuss matters regarding risk management.

An Operational Risk Committee ("ORC") is established to provide governance and oversight of the operational risk management activities within the Company by ensuring the operational risk management activities are governed by the guiding principles and processes in the Company's Enterprise Risk Management Framework, with the emphasis of operational risks.

Whilst the Risk Management Department spearheads the development and implementation of the Framework and Risk Management Policy of the Company, the Senior Management remains accountable and responsible for the development of detailed policies, procedures and limits for managing risks inherent in the Company's activities based on the business and risk management strategies approved by the Board.

Consistent with the provisions set out in the guidelines, the Company's operational management or business lines, typically known as the first line of defense, are accountable for the day-to-day management of business activities and all types of risks associated with these activities within the established limits. The Risk Management and Compliance functions, typically known as the second line of defense, are accountable for ensuring adequate programs are in place in exercising its control and oversight responsibilities. The internal audit function, typically known as the third line of defense are accountable for providing the Board with an independent assurance that the risk management and oversight approach undertaken, system of internal controls, governance process of the Company are adequate and effective.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 **RISK MANAGEMENT FRAMEWORK (CONTINUED)**

(e) **Insurance risks of life insurance contracts**

The Company is exposed to life insurance risks when it signs a contract with the insured party or policyholder for a premium amount and in return promises to compensate the policyholder if a specified uncertain future event or an insured event adversely affects the policyholder. Life insurance risks arise when the prices charged for life insurance contracts may be ultimately inadequate to support the future contractual obligations due to adverse deviation of the assumptions used in pricing the insurance contracts from the actual experience. Assumptions used in product pricing include items such as policy lapses, policy claims such as mortality and morbidity, expenses as well as investment return and discount rate.

Experience studies are carried out annually to ensure that pricing assumptions are adequate, appropriate and consistent with the actual experience for insurance product pricing purposes.

The Company has implemented underwriting and claims management guidelines and procedures to manage its life insurance risks. Whilst proper underwriting process is put in place to control the risk of anti-selection, appropriate claims management also help to identify fraudulent claims.

The mortality and morbidity risks are also managed through reinsurance programme. The bulk of the Company's reinsurance is in the form of automatic treaties. These treaties are of risk premium type and cover both individual business and group business. In addition, there is another layer of reinsurance that is in the form of a catastrophe treaty. Both of these types of reinsurance serve to protect the Company's solvency, especially when there is an accumulation of risk, for example a natural disaster.

A substantial portion of the Company's life insurance funds is participating in nature. In the event of volatile investment climate and/or unusual claims experience, the Company has the option of revising the bonus rates and dividends payable to the policyholders.

For non-participating funds, the risk is that policy benefits are guaranteed to the policyholders and these obligations must be fulfilled in spite of the Company's poor investment performance or unfavorable claims experience. To mitigate this risk, investment mandate is put in place to ensure that appropriate investment strategy that focuses on Low Risk Assets ("LRA") and Private Debt Securities ("PDS") assets with minimum equity exposure is adopted by the fund managers.

For investment-linked funds, the risk exposure for the Company is limited only to the underwriting aspect as all investment risks are borne by the policyholders and proper expense management is in place to minimise actual costs incurred.

The BNM's Policy Document of Stress Testing provides standards and guidance for the insurance industry in conducting stress testing to support a licensed person's risk and capital management. The purpose of Stress Testing is to test the solvency of life insurance funds under various scenarios according to the prescribed statutory valuation basis, simulating drastic changes in major parameters like interest rates, investment return, inflation rate, investment asset value, new business volume, mortality/morbidity patterns as well as expense patterns. In addition, stress testing also provides an early warning signal for the Company to take necessary measures to protect its financial position.

Registration No.

1993010222976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(e) Insurance risks of life insurance contracts (continued)

The table below shows the concentration actuarial liabilities by type of contract.

	Gross			Reinsurance			Net RM'000
	With DPF RM'000	Without DPF RM'000	Total RM'000	With DPF RM'000	Without DPF RM'000	Total RM'000	
31 December 2021							
Whole Life	290,359	94,671	385,030	-	-	-	385,030
Endowment	403,534	169,517	573,051	-	-	-	573,051
Term - Mortgage	-	164,877	164,877	-	-	-	164,877
Term - Others	47	11,712	11,759	-	-	-	11,759
M&H	-	296	296	-	-	-	296
Riders	152	51,125	51,277	-	-	-	51,277
Other Provision	5,867	101,800	107,667	(113)	(5,943)	(6,056)	101,611
Total insurance contract liabilities	699,959	593,998	1,293,957	(113)	(5,943)	(6,056)	1,287,901
31 December 2020							
Whole Life	294,759	97,297	392,056	-	-	-	392,056
Endowment	411,363	175,198	586,561	-	-	-	586,561
Term - Mortgage	-	191,876	191,876	-	-	-	191,876
Term - Others	41	21,169	21,210	-	-	-	21,210
M&H	-	139	139	-	-	-	139
Riders	(66)	46,036	45,970	-	-	-	45,970
Other Provision	11,095	124,558	135,653	(109)	(6,209)	(6,318)	129,335
Total insurance contract liabilities	717,192	656,273	1,373,465	(109)	(6,209)	(6,318)	1,367,147

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 **RISK MANAGEMENT FRAMEWORK (CONTINUED)**

(e) **Insurance risks of life insurance contracts (continued)**

As all of the business is derived from Malaysia, the entire life insurance contract liabilities are in Malaysia.

Key assumptions

Material judgement is required in determining the liabilities and in the choice of assumptions. Valuation assumptions used are based on past experience, current internal data, external market indices and benchmarks which reflect current observable market prices and other published information. Valuation assumptions and prudent estimates are determined at the date of valuation. Valuation assumptions are further evaluated on a continuous basis in order to ensure realistic and reasonable valuations.

The key assumptions to which the estimation of liabilities is particularly sensitive are as below:

(i) Mortality rates

Best estimate assumptions are based on the Company's recent experience studies.

(ii) Expenses

Best estimate assumptions are based on the experience of the Company and long-term expected expenses levels. An inflation rate of 2.5% per annum is assumed over time. Allowance is also made for payment of commission to distributors.

(iii) Lapse and surrender rates

Best estimate assumptions are based on the experience studies. The Company conducts a persistency study annually, or on a more regular basis when appropriate. Statistical methods are used to determine appropriate lapse and surrender rates. Lapse and surrender rates vary by product type and policy duration.

(iv) Discount rate

Risk free discount rate is used in the valuation of actuarial liabilities for non-participating fund and the non-unit liabilities of investment-linked funds and the guaranteed benefit liabilities of participating funds.

These risk free rates from durations of 1 to 15 years are the MGS yields taken from Bond Pricing Agency Malaysia, which is a recognised bond pricing agency in Malaysia. Interpolation or extrapolation is used to determine yields for terms where MGS yields are not available. For cash flows with duration of 15 years or more, the 15-year MGS yield is used for discounting purposes.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(e) Insurance risks of life insurance contracts (continued)

(v) Fund based yield

Fund based yield is used in the valuation of actuarial liabilities for participating fund to discount expected cashflows for future years. Expected cashflows include an allowance for non-guaranteed benefits. The selected yield reflects the expected return on participating fund, based on investment strategy employed, and can be differentiated between groups of products to reflect characteristics of the products, which may affect the investment strategy employed. The yield is reduced to allow for expected tax on investment income.

(vi) Sensitivities

The analysis below is performed for reasonably possible movements in key assumptions with all other assumptions held constant, showing the impact on gross and net liabilities. No management actions (e.g. possible revision of bonus rates for participating fund products) have been assumed in the calculation of net and gross liabilities. The correlation of assumptions will have a significant effect in determining the ultimate claims liabilities, but to demonstrate the impact due to changes in assumptions, assumptions had to be changed on an individual basis. It should be noted that movements in these assumptions are non-linear. Sensitivity information will also vary according to the current economic assumptions.

	Impact on change in assumptions	Impact on gross liabilities	Impact on net liabilities	Impact on profit after tax	Impact on equity
<u>31 December 2021</u>					
Mortality/morbidity	+25%	67,180	67,180	(50,445)	(50,445)
Expenses	+25%	30,257	30,257	(20,280)	(20,280)
Lapse and surrender rates	+25%	(1,495)	(1,495)	(2,044)	(2,044)
Discount rate	-1%	65,800	65,800	(37,425)	(37,425)
<u>31 December 2020</u>					
Mortality/morbidity	+25%	63,435	63,435	(47,771)	(47,771)
Expenses	+25%	33,105	33,105	(22,469)	(22,469)
Lapse and surrender rates	+25%	(5,298)	(5,298)	876	876
Discount rate	-1%	72,403	72,403	(42,968)	(42,968)

The method used and significant assumptions made for deriving sensitivity information did not change from the previous period.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(f) Financial Risk

(i) Credit risk

Credit risk is the potential financial loss resulting from counterparty's inability or unwillingness to fully meet its contractual financial obligations as and when they fall due. The counterparties may include debtors, borrowers, brokers, policyholders, reinsurers and guarantors.

The Company's primary exposure to credit risk is through its investments in fixed income securities, lending activities such as policy loans are secured against the surrender value of policies and carry no substantial credit risk and potential obligations of reinsurers arising out of reinsurance arrangements.

The Company's Investment Committee manages credit risk associated with investments in fixed income securities through the setting of investment policies as well as credit exposure limits approved by the Board and within the guidelines issued by BNM.

Credit evaluation of an issuer of credit facilities is undertaken by the Investment Department. The credit profile of an issuer is assessed by considering factors such as industry and business background, operating performance or viability of a project, business risk factors, financial ratio analysis, financial strength and flexibility, availability of cash flows and identified sources of repayment, management credibility and shareholders' profile as well as security enhancement.

In addition, a credit review of individual exposure is also conducted by the investment team at least once a year to review and monitor the creditworthiness of issuers or counterparties. Additional review will be carried out when there is a downgrade of credit rating, a change in the nature of an issuer's business or a corporate restructuring of an issuer.

Reinsurance programme is arranged with reinsurers that have a good credit rating in order to reduce credit risk arising from reinsurance arrangements.

Credit risk in respect of policyholder balances incurred on non-payment of premiums or contributions will only persist during the grace period specified in the policy document until expiry, when the policy is either paid up or terminated.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(f) **Financial Risk (continued)**

(i) **Credit risk (continued)**

Credit exposure

The table below shows the maximum exposure to credit risk for the components on the statement of financial position.

	Life and Shareholders' Funds RM'000	Investment- linked Funds RM'000	Total RM'000
<u>31 December 2021</u>			
HTM financial assets:			
Malaysian government guaranteed bonds	10,011	-	10,011
Debt securities	174,447	-	174,447
Accrued interest	3,227	-	3,227
LAR:			
Loans	43,871	-	43,871
Fixed and call deposits	1,147	-	1,147
Accrued interest	15,779	-	15,779
AFS financial assets:			
Debt securities	378,918	-	378,918
Malaysian Government Securities	10,450	-	10,450
Malaysian government guaranteed bonds	659,480	-	659,480
Accrued interest	10,799	-	10,799
FVTPL financial assets:			
Debt securities	-	30,012	30,012
Accrued interest	-	319	319
Reinsurance assets	12,543	-	12,543
Insurance receivables	3,558	-	3,558
Other receivables	6,161	14,193	20,354
Cash and cash equivalents	196,668	2,346	199,014
	<u>1,527,059</u>	<u>46,870</u>	<u>1,573,929</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(f) Financial Risk (continued)

(i) Credit risk (continued)

Credit exposure (continued)

The table below shows the maximum exposure to credit risk for the components on the statement of financial position. (continued)

	Life and Shareholders' Funds RM'000	Investment- linked Funds RM'000	Total RM'000
<u>31 December 2020</u>			
HTM financial assets:			
Malaysian government guaranteed bonds	10,012	-	10,012
Debt securities	184,779	-	184,779
Accrued interest	3,300	-	3,300
LAR:			
Loans	43,959	-	43,959
Fixed and call deposits	1,127	-	1,127
Accrued interest	15,111	-	15,111
AFS financial assets:			
Debt securities	417,365	-	417,365
Malaysian Government Securities	11,312	-	11,312
Malaysian government guaranteed bonds	664,621	-	664,621
Accrued interest	10,525	-	10,525
FVTPL financial assets:			
Debt securities	-	30,648	30,648
Accrued interest	-	334	334
Reinsurance assets	12,567	-	12,567
Insurance receivables	7,048	-	7,048
Other receivables	13,989	14,047	28,036
Cash and cash equivalents	165,555	1,832	167,387
	<u>1,561,270</u>	<u>46,861</u>	<u>1,608,131</u>

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(f) Financial Risk (continued)

(i) Credit risk (continued)

Credit exposure by credit rating

The table below provides information regarding the credit risk exposure of the Company by classifying assets according to the Company's credit ratings of counterparties.

	Neither past due nor impaired Investment grade (AAA to A) RM'000	Not rated RM'000	Investment- linked RM'000	Impaired RM'000	Total RM'000
31 December 2021					
HTM financial assets					
Malaysian government guaranteed bonds	-	10,011	-	-	10,011
Debt securities	174,447	-	-	-	174,447
Accrued interest	3,058	169	-	-	3,227
LAR					
Loans	-	43,871	-	-	43,871
Fixed and call deposits	1,147	-	-	-	1,147
Accrued interest	-	15,779	-	-	15,779
AFS financial assets					
Debt securities	372,380	-	-	6,538	378,918
Malaysian Government Securities	-	10,450	-	-	10,450
Malaysian government guaranteed bonds	10,559	648,921	-	-	659,480
Accrued interest	3,804	6,995	-	-	10,799
FVTPL financial assets					
Debt securities	-	-	30,012	-	30,012
Accrued interest	-	-	319	-	319
Reinsurance assets	111	12,432	-	-	12,543
Insurance receivables	3,558	-	-	-	3,558
Other receivables	5,800	361	14,193	-	20,354
Cash and cash equivalents	191,362	5,306	2,346	-	199,014
	766,226	754,295	46,870	6,538	1,573,929

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

- (f) Financial Risk (continued)
(i) Credit risk (continued)

Credit exposure by credit rating (continued)

The table below provides information regarding the credit risk exposure of the Company by classifying assets according to the Company's credit ratings of counterparties. (continued)

	Neither past due nor impaired				Total RM'000
	Investment grade (AAA to A) RM'000	Non-investment grade (BBB and below) RM'000	Not rated RM'000	Investment- linked RM'000	
<u>31 December 2020</u>					
HTM financial assets					
Malaysian government guaranteed bonds	-	-	10,012	-	10,012
Debt securities	184,779	-	-	-	184,779
Accrued interest	3,131	-	169	-	3,300
LAR					
Loans	-	-	43,959	-	43,959
Fixed and call deposits	1,127	-	-	-	1,127
Accrued interest	-	-	15,111	-	15,111
AFS financial assets					
Debt securities	406,780	10,585	-	-	417,365
Malaysian Government Securities	-	-	11,312	-	11,312
Malaysian government guaranteed bonds	11,176	-	653,445	-	664,621
Accrued interest	3,937	-	6,588	-	10,525
FVTPL financial assets					
Debt securities	-	-	-	30,648	30,648
Accrued interest	-	-	-	334	334
Reinsurance assets	6,249	-	6,318	-	12,567
Insurance receivables	7,048	-	-	-	7,048
Other receivables	13,866	-	123	14,047	28,036
Cash and cash equivalents	161,029	-	4,526	1,832	167,387
	<u>799,122</u>	<u>10,585</u>	<u>751,563</u>	<u>46,861</u>	<u>1,608,131</u>

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(f) Financial Risk (continued)

(ii) Liquidity risk

Liquidity risk is the risk of exposure to losses in the event that insufficient liquid asset will be available from among the assets supporting the policy obligations to meet the cash flow requirements of the obligations to policyholders when they fall due. For example, lower than expected investment income to meet claims necessitate unexpected realisation of assets. Unexpected demands for liquidity may also be triggered by market conditions that encourage widespread exercise of embedded options, adverse change in the surrender rate as well as uncertainty in the level of new business growth.

The Company monitors its liquidity risk and maintains a level of cash and cash equivalents deemed adequate by the management to finance its operations and to mitigate the effects of fluctuations in cash requirements. Liquidity management requires the Company to maintain a liquid position at all times to meet unexpected claims payments when they fall due and simultaneously hold an asset mix that meets the Company's target return.

The Company manages its liquidity risk by maintaining an adequate level of cash and cash equivalents. The liquidity risk is also minimised by close monitoring of surrenders and redemptions.

In addition, guidelines on asset allocation, portfolio limit structure and maturity profile of assets are also put in place to ensure sufficient funding is available to meet insurance and investment contracts' obligations. Compliance with the guidelines and policies, exposures and breaches are monitored and reported regular basis to the Company's Management Investment Committee ("MIC").

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

- (f) Financial Risk (continued)
(ii) Liquidity risk (continued)

Maturity analysis

Below is the summary table for the maturity profile of the financial assets and liabilities based on remaining undiscounted contractual obligations, including interest/profit payable and receivable. For insurance contracts liabilities, maturity profiles are determined based on estimated timing of net cash outflows from the recognised insurance liabilities. Unit-linked liabilities are repayable or transferable on demand and are included in the "Current" column. Repayments which are subject to notice are treated as if notice were to be given immediately.

	Carrying Value RM'000	Current RM'000	1 – 5 years			5 – 15 years		Over 15 years		No maturity date RM'000	Total RM'000
			1 – 5 years	5 – 15 years	Over 15 years	RM'000	RM'000	RM'000			
31 December 2021											
Financial instruments:											
HTM	184,458	20,828	103,805	99,258	-	-	-	-	-	223,891	
LAR	45,018	1,147	-	-	-	-	-	-	43,871	45,018	
AFS	1,052,193	55,591	349,029	819,490	258,397	-	-	-	-	1,483,507	
FVTPL	647,952	829	12,042	18,480	22,883	-	-	-	617,940	672,174	
Accrued Interest:											
HTM	3,227	3,227	-	-	-	-	-	-	-	3,227	
LAR	15,779	15,779	-	-	-	-	-	-	-	15,779	
AFS	10,799	10,799	-	-	-	-	-	-	-	10,799	
FVTPL	319	319	-	-	-	-	-	-	-	319	
Reinsurance assets	12,543	12,543	-	-	-	-	-	-	-	12,543	
Insurance receivables	3,558	3,558	-	-	-	-	-	-	-	3,558	
Other receivables	20,354	20,110	244	-	-	-	-	-	-	20,354	
Cash and cash equivalents	199,014	199,014	-	-	-	-	-	-	-	199,014	
Financial assets	2,195,214	344,744	465,120	937,228	281,280	-	-	-	661,811	2,690,183	

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

- (f) Financial Risk (continued)
(ii) Liquidity risk (continued)

Maturity analysis (continued)

Below is the summary table for the maturity profile of the financial assets and liabilities based on remaining undiscounted contractual obligations, including interest/profit payable and receivable. For insurance contracts liabilities, maturity profiles are determined based on estimated timing of net cash outflows from the recognised insurance liabilities. Unit-linked liabilities are repayable or transferable on demand and are included in the "Current" column. Repayments which are subject to notice are treated as if notice were to be given immediately. (continued)

	Carrying Value RM'000	Current RM'000	1 – 5 years RM'000	5 – 15 years RM'000	Over 15 years RM'000	No maturity date RM'000	Total RM'000
<u>31 December 2021</u>							
Insurance contract liabilities	1,832,926	459,304	583,184	588,914	624,663	-	2,256,065
Insurance payables	32,533	20,954	761	5,052	5,766	-	32,533
Lease liabilities	19,485	3,923	14,003	4,928	-	-	22,854
Other payables	22,879	22,879	-	-	-	-	22,879
Financial liabilities	<u>1,907,823</u>	<u>507,060</u>	<u>597,948</u>	<u>598,894</u>	<u>630,429</u>	<u>-</u>	<u>2,334,331</u>

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

- (f) Financial Risk (continued)
(ii) Liquidity risk (continued)

Maturity analysis (continued)

Below is the summary table for the maturity profile of the financial assets and liabilities based on remaining undiscounted contractual obligations, including interest/profit payable and receivable. For insurance contracts liabilities, maturity profiles are determined based on estimated timing of net cash outflows from the recognised insurance liabilities. Unit-linked liabilities are repayable or transferable on demand and are included in the "Current" column. Repayments which are subject to notice are treated as if notice were to be given immediately. (continued)

	Carrying Value RM'000	Current RM'000	1 - 5 years			5 - 15 years		Over 15 years		No maturity date RM'000	Total RM'000
			1 - 5 years RM'000	1 - 5 years RM'000	5 - 15 years RM'000	5 - 15 years RM'000	Over 15 years RM'000	Over 15 years RM'000			
31 December 2020											
Financial instruments:											
HTM	194,791	15,748	85,782	139,400	-	-	-	-	-	240,930	
LAR	45,086	1,127	-	-	-	-	-	-	43,959	45,086	
AFS	1,096,580	46,337	307,313	845,016	299,485	-	-	-	30,926	1,529,077	
FVTPL	611,077	1,674	6,073	18,768	8,074	-	-	-	580,429	615,018	
Accrued interest:											
HTM	3,300	3,300	-	-	-	-	-	-	-	3,300	
LAR	15,111	15,111	-	-	-	-	-	-	-	15,111	
AFS	10,525	10,525	-	-	-	-	-	-	-	10,525	
FVTPL	334	334	-	-	-	-	-	-	-	334	
Reinsurance assets	12,567	12,567	-	-	-	-	-	-	-	12,567	
Insurance receivables	7,048	7,048	-	-	-	-	-	-	-	7,048	
Other receivables	28,036	27,768	268	-	-	-	-	-	-	28,036	
Cash and cash equivalents	167,387	167,387	-	-	-	-	-	-	-	167,387	
Financial assets	2,191,842	308,926	399,436	1,003,184	307,559	-	-	-	655,314	2,674,419	

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

- (f) Financial Risk (continued)
(iii) Liquidity risk (continued)

Maturity analysis (continued)

Below is the summary table for the maturity profile of the financial assets and liabilities based on remaining undiscounted contractual obligations, including interest/profit payable and receivable. For insurance contracts liabilities, maturity profiles are determined based on estimated timing of net cash outflows from the recognised insurance liabilities. Unit-linked liabilities are repayable or transferable on demand and are included in the "Current" column. Repayments which are subject to notice are treated as if notice were to be given immediately. (continued)

	Carrying Value RM'000	Current RM'000	RM'000				No maturity date RM'000	Total RM'000
			1 – 5 years	5 – 15 years	Over 15 years			
<u>31 December 2020</u>								
Insurance contract liabilities	1,889,632	478,014	564,705	614,074	614,069	-	2,270,862	
Insurance payables	45,224	30,492	455	8,306	5,971	-	45,224	
Lease liabilities	21,625	3,940	13,806	8,339	-	-	26,085	
Other payables	21,657	21,657	-	-	-	-	21,657	
Financial liabilities	1,978,138	534,103	578,966	630,719	620,040	-	2,363,828	

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(f) Financial Risk (continued)

(iii) Market risk

Market risk is the risk that the fair value of assets or future cash flows of assets supporting the insurance/investment contract liabilities, or the carrying value of the contract liabilities will fluctuate because of changes in market prices and rates. These include changes in equity prices, interest rates and exchange rates. Market risk also includes such factors as changes in economic environment, consumption pattern and investor's expectation that may have significant impact on the value of the investments.

The Company distinguishes market risk as follows:

- (a) Interest rate risk;**
- (b) Equity price risk; and**
- (c) Currency risk.**

The Company manages market risk by putting in place investment mandates and policies to ensure that appropriate investment strategy is adopted by the fund managers. In addition, asset allocation, portfolio and exposure limit structure as well as performance benchmark are also set to ensure that assets support the specific contract liabilities and that assets held are adequate and sufficient to deliver income and gains to policyholders in accordance with the terms of respective contracts and in line with the policyholders' expectations. Compliance with the investment mandates and policies is monitored and reported regularly to the Company's MIC and exposures and breaches are reported as soon as practicable.

The Company also issues investment-linked policies. In the investment-linked business, the policyholders bear the investment risk on the assets held in the investment-linked funds as the policy benefits are directly linked to the net asset value of the funds. The Company's exposure to market risk on this business is therefore limited to the extent that income arising from asset management charges is based on the net asset value of the funds.

(a) Interest rate risk

The Company is exposed to interest rate risk primarily through investments of insurance funds in fixed income securities, credit facilities as well as cash deposits.

The presence of interest rate risk is the result of asset-liability duration mismatch. To illustrate, since the duration of contract liabilities is longer than the duration of assets, the Company's financial position is vulnerable to decrease in interest rates. When interest rates fall, the value of liabilities will increase significantly more than the value of assets due to the asset-liability duration mismatch, thus reducing the insurance fund's surplus.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(f) Financial Risk (continued)

(iii) Market risk (continued)

(a) Interest rate risk (continued)

As one of the reasons for asset-liability duration mismatch is the scarcity of longer tenure assets in the local financial market, the Company has adopted investment strategy that focuses on identifying suitable investment opportunities which can lengthen the duration of assets and acquiring longer tenure assets whenever available so as to mitigate interest rate risk.

The Company also manages its interest rate risk by calculating the asset and liability durations and monitoring the duration gap and periodic basis.

The Company has no significant concentration of interest rate risk.

The sensitivity analysis below is performed for reasonably possible movements in key variables with all other variables held constant, showing the impacts for the financial year ended:

<u>Change in variables</u>	<u>Impact on profit after tax</u>	<u>Impact on equity</u>	<u>Impact on insurance contract liabilities</u>
	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>
<u>31 December 2021</u>			
+50 basis points	(10,664)	(57,740)	(45,862)
-50 basis points	13,144	75,943	66,165
<u>31 December 2020</u>			
+50 basis points	(10,800)	(54,076)	(45,760)
-50 basis points	12,339	67,847	64,034

In the above analysis, the impact arising from changes in interest rate risk to fixed income securities and liabilities of the life participating and investment-linked funds are retained in the life insurance contract liabilities. The impact to the Company's profit after tax and equity arise from the investment in fixed income securities of the funds other than life participating and investment-linked funds.

The method used for deriving sensitivity information and significant variables did not change from the previous period.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(f) Financial Risk (continued)

(iii) Market risk (continued)

(b) Equity price risk

The Company is exposed to equity price risk through direct investments in equity of listed and unlisted companies by both life insurance funds and shareholders' fund as the Company bears some of the volatility in returns and investment performance risk.

Equity price risk also exists in investment-linked products as the revenue of the insurance operations are linked to the value of the underlying equity funds and this has an impact on the level of fees earned.

The Company monitors its equity exposure against a benchmark set and agreed by the MIC. The portfolio benchmarks include indices such as the Kuala Lumpur Composite Index and the FTSE Bursa Malaysia Index.

The Company's investment policy also requires it to manage market risk by monitoring the asset class limit and single security exposure of the portfolio against the internal investment limits as well as regulatory limits stipulated by BNM. The Company has complied with both the internal and BNM stipulated investment limits during the financial year and has no significant concentration of equity price risk.

The sensitivity analysis below is performed for reasonably possible movements in key variables with all other variables held constant, showing the impacts for the financial year ended:

	Changes in variables	Impact on profit after tax	Impact on equity	Impact on insurance contract liabilities
31 December 2021		RM'000	RM'000	RM'000
Bursa Malaysia	30%	38,593	38,593	125,370
Bursa Malaysia	-30%	(38,593)	(38,593)	(125,370)
31 December 2020				
Bursa Malaysia	30%	35,766	35,766	118,442
Bursa Malaysia	-30%	(35,766)	(35,766)	(118,442)

The potential impact arising from other market indices are deemed insignificant as the Company's holdings in equity securities listed in other bourses are not material.

The method used for deriving sensitivity information and significant variables did not change from the previous period.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(f) **Financial Risk (continued)**

(iii) **Market risk (continued)**

(c) **Currency risk**

Currency risk is the risk that relative changes in currency values will ultimately decrease the value of foreign assets or increase the value of financial obligations denominated in foreign currencies.

As the Company operates mainly in Malaysia, its financial assets are primarily maintained in Malaysia as required under the FSA, and are primarily denominated in the same currency (the local RM) as its insurance and investment contract liabilities. Therefore, the main foreign exchange risk from recognised assets and liabilities arises from transactions other than those in which the insurance and investment contract liabilities are expected to be settled.

The Company does not engage in derivative transactions for speculative or hedging purposes.

As the Company's main foreign exchange risk from recognised assets and liabilities arises from reinsurance transactions for which the balances are expected to be settled and realised in less than a year, the impact arising from sensitivity in foreign exchange rates is deemed minimal as the Company has no significant concentration of foreign currency risk.

In the investment-linked business, the policyholders bear the currency risk on the foreign assets held in some of the investment-linked funds as the policy benefits are directly linked to the net asset value of the funds. The Company's exposure to currency risk on this business is therefore limited to the extent that income arising from asset management charges is based on the net asset value of the funds.

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

32 RISK MANAGEMENT FRAMEWORK (CONTINUED)

(g) Operational risk

Operational risk may be defined as the risk of loss arising from system failure, inadequate or failed internal processes, human factors, from internal and/or external events. When the controls measures in place are inadequate or poorly implemented, it may expose the Company to Operational Risks. These Operational Risks, if materialised, may lead to both financial and/or non-financial losses.

In mitigating this, the Company ensures the controls are implemented when discharging.

Business and operational activities continue to be relevant and effective. The manner in which operational risk is managed can be best demonstrated through implementation of proper governance structure, supported by over-arching framework of policies, procedures and standards. Some of the controls being implemented include clear reporting lines, proper segregation of duties and responsibilities, adequate check and balance, properly defined role-based access controls, authorisation and reconciliation procedures, staff training and evaluation procedures to name a few.

In order to gauge the effectiveness of the controls being put in place, all business and/or Operational Head perform thorough risk identification and assessment of risk. In order to mitigate of identified risks (moderate and above), the Business and/or Operational Heads will assess and implement mitigation action plans to manage the risk to within acceptable limits.

The Risk Management and Compliance functions continue to play proactive role in ensuring that proper programs are in place to instill the right control culture within the Company and at the same time, works with the Business and/or Operational Heads to assess the appropriateness of controls and remedial action plans being implemented in mitigating the risks, consistent with its control and oversight responsibilities.

The Internal Audit function will perform its independent assurance work to ensure that the risk management and oversight approach undertaken, systems of internal controls, governance process of the Company are adequate, relevant and effective in managing the risks.

(h) Strategic risk

Strategic risk is the risk of loss arising from adverse business decisions, improper implementation of those decisions, and lack of responsiveness to industry or competitive environmental changes. This risk is monitored through the Company's strategic planning and budgeting process.

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

33

INSURANCE FUNDS

The Company's activities are organised by funds and segregated into the life and shareholders' fund in accordance with FSA.

**Statement of Financial Position by Funds
For the financial year ended**

	Shareholders' Fund		Life Funds		Investment-linked Funds		Elimination		Total	
	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000
Assets										
Properties and equipment	-	-	3,335	11,397	-	-	-	-	3,335	11,397
Investment property	-	-	5,400	5,200	-	-	-	-	5,400	5,200
Intangible assets	-	-	7,833	3,658	-	-	-	-	7,833	3,658
Prepaid lease property	-	-	-	221	-	-	-	-	-	221
Right-of-use asset	-	-	-	20,308	-	-	-	-	-	20,308
Investments	170,712	163,139	1,509,531	1,552,398	286,079	267,912	(6,577)	(6,645)	1,959,745	1,976,804
Reinsurance assets	-	-	12,543	12,567	-	-	-	-	12,543	12,567
Insurance receivables	-	-	3,558	7,048	-	-	-	-	3,558	7,048
Other receivables	68,761	37,850	6,162	13,989	14,281	13,700	(68,850)	(37,503)	20,354	28,036
Cash and cash equivalents	73,877	35,465	122,791	130,089	2,346	1,833	-	-	199,014	167,387
Total Assets	313,350	236,454	1,694,770	1,756,875	302,706	283,445	(75,427)	(44,148)	2,235,399	2,232,626
Share capital	185,000	125,000	-	-	-	-	-	-	185,000	125,000
Retained earnings	100,526	67,327	-	-	-	-	-	-	100,526	67,327
AFS fair value reserves	14,504	35,004	-	-	-	-	-	-	14,504	35,004
Asset revaluation reserves	44	46	-	-	-	-	-	-	44	46
Total Equity	300,074	227,377	-	-	-	-	-	-	300,074	227,377
Insurance contract liabilities	-	-	1,544,261	1,620,571	295,242	275,706	(6,577)	(6,645)	1,832,926	1,899,632
Deferred tax liabilities	12,726	7,264	5,450	9,978	7,331	6,862	-	-	25,507	24,104
Insurance payables	89	73	32,533	45,165	-	-	-	-	32,533	45,224
Tax payable	461	1,681	1,906	2,934	133	877	(68,850)	(37,503)	1,995	3,007
Other payables	-	-	91,135	56,602	-	-	-	-	22,879	21,657
Lease liabilities	-	-	19,485	21,625	-	-	-	-	19,485	21,625
Total Liabilities	13,276	9,077	1,694,770	1,756,875	302,706	283,445	(75,427)	(44,148)	1,935,325	2,005,249
Total Policyholders' Funds and Liabilities	313,350	236,454	1,694,770	1,756,875	302,706	283,445	(75,427)	(44,148)	2,235,399	2,232,626

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

33 INSURANCE FUNDS (CONTINUED)

Statement of Income by Funds
For the financial year ended

	Shareholders' Fund		Life Funds		Investment-Linked Funds		Elimination		Total	
	2021	2020	2021	2020	2021	2020	2021	2020	2021	2020
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Operating revenue	4,527	5,318	233,026	250,432	40,825	36,133	-	-	278,380	291,883
Gross premiums	-	-	162,779	180,184	35,967	31,803	-	-	198,746	211,987
Premiums ceded to reinsurers	-	-	(11,004)	(11,126)	-	-	-	-	(11,004)	(11,126)
Net premiums	-	-	151,775	169,058	35,967	31,803	-	-	187,742	200,861
Investment income	4,527	5,318	70,249	70,248	4,858	4,330	-	-	79,634	79,896
Realised gains	4	35	13,917	10,568	21,821	23,354	-	-	35,742	33,957
Fair value (loss)/gain	(1,302)	144	(4,767)	15,650	5,874	39,169	67	(297)	(128)	54,666
Other operating income	(7,491)	(7,474)	11,555	10,680	-	-	-	-	4,064	3,206
Other income	(4,262)	(1,977)	90,954	107,146	32,553	66,853	67	(297)	119,312	171,725
Gross benefits and claims	-	-	(144,917)	(207,685)	(42,681)	(36,697)	-	-	(187,598)	(244,382)
Claims ceded to reinsurers	-	-	5,639	7,425	-	-	-	-	5,639	7,425
Gross change in contract liabilities	-	-	57,319	(68,997)	(19,536)	(53,607)	(67)	297	37,716	(122,307)
Change in contract liabilities to reinsurers	-	-	(262)	(1,096)	-	-	-	-	(262)	(1,096)
Net insurance benefits and claims	-	-	(82,221)	(270,353)	(62,217)	(90,304)	(67)	297	(144,505)	(360,360)

Registration No.

199301022976 (277714-A)

GIBALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)**

33 INSURANCE FUNDS (CONTINUED)

**Statement of Income by Funds
For the financial year ended (continued)**

	Shareholders' Fund		Life Funds		Investment-Linked Funds		Elimination		Total	
	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000	2021 RM'000	2020 RM'000
Fee and commission expenses	(1,926)	(1,105)	(10,777)	(12,535)	-	-	-	-	(12,703)	(13,640)
Management expenses	(2,566)	(2,401)	(89,369)	(93,765)	(4,029)	(3,241)	-	-	(95,966)	(99,407)
Other expenses	(4,494)	(3,506)	(100,146)	(106,300)	(4,029)	(3,241)	-	-	(108,669)	(113,047)
(Loss)/profit before taxation	(8,756)	(5,483)	60,362	(100,449)	2,274	5,111	-	-	53,880	(100,821)
Transfer from revenue accounts	55,621	(107,260)	(55,621)	107,260	-	-	-	-	-	-
Profit/(loss) before taxation	46,865	(112,743)	4,741	6,811	2,274	5,111	-	-	53,880	(100,821)
Tax (expense)/benefit	(13,666)	20,066	(4,741)	(6,811)	(2,274)	(5,111)	-	-	(20,681)	8,144
Profit/(loss) for the financial year	33,199	(92,677)	-	-	-	-	-	-	33,199	(92,677)

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

34 ADDITIONAL DISCLOSURE UNDER AMENDMENTS TO MFRS 4 INSURANCE CONTRACT LIABILITIES

The Company has applied the temporary exemption from the adoption of MFRS 9 "Financial Instruments" from 1 January 2018 to no later than 1 January 2023.

In order to compare with entities applying MFRS 9, the amendments require deferring entities to disclose additional information including contractual cash flows characteristics and credit exposure of the financial assets.

The following table presents the Company's financial assets by their contractual cash flows characteristics, which indicate if they are solely payments of principal and interest on the principal outstanding ("SPPI"):

Financial assets	Fair value as at 31.12.2021	Change in fair value	Cash flows characteristics
	RM'000	RM'000	
Malaysian government securities	10,450	(886)	SPPI
Malaysian government guaranteed bonds	676,972	(40,482)	SPPI
Unquoted debt securities	569,059	(28,127)	SPPI
Quoted equity securities	417,826	(38,688)	NON SPPI
Quoted unit trust and property trust funds	200,115	10,566	NON SPPI
Unquoted equity securities	3,345	-	NON SPPI
Fixed and call deposits	1,147	-	SPPI
Loans and receivables ("LAR")	59,650	-	SPPI
Cash and cash equivalents	199,014	-	SPPI
	<u>2,137,578</u>	<u>(97,617)</u>	

Insurance receivables and reinsurance assets have been excluded from the above assessment as they are under the scope of MFRS 4 – Insurance Contracts.

Other than the financial assets included in the table above and assets that are within the scope of MFRS 4, all other assets in the statement of financial position are non-financial asset.

All financial assets with SPPI cash flows of the Company as at 31 December 2021 have low credit risk and are disclosed in Note 32 to the financial statements.

Registration No.

199301022976 (277714-A)

GIBRALTAR BSN LIFE BERHAD
(Incorporated in Malaysia)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021 (CONTINUED)

35 SIGNIFICANT EVENT

The rising Covid-19 cases led to a nationwide total lockdown on all social and economic sectors in Malaysia on 28 May 2021.

Although the Company operates as an essential service provider, the operating environment is challenging given economic concerns which affects consumer sentiments.

The pandemic had resulted in uncertainty over the global and local economic outlook, contributes to higher volatility and the low interest rate environment.

While the Company's financial results for the period are still healthy, actions are taken in managing the business and operations to remain resilient.

The Company will continue to monitor the impact of the pandemic and take appropriate mitigating actions such as focus on driving business growth, cautiously managing operating expenses, and remain available to serve our customers.